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Germinal Center B-cells (GCB) arise upon antigen stimulation and undergo 
somatic hypermutation (SHM) in order to produce high-affinity antibodies. BCL6, a 
transcriptional repressor, sustains GCB survival despite the genotoxic stress associated 
with SHM by repressing apoptosis and cell cycle arrest genes.  
 
Studies from our lab show intra-chromosomal interactions between a putative 
locus control region (LCR) and the BCL6 promoter in human GCBs. In both human 
and mice, this LCR is characterized by histone modifications associated with active 
enhancers, DNase hypersensitive regions, and increased binding of transcription 
factors and chromatin modifiers. This evidence suggested that the LCR is ‘switched 
on’ during the transition from naïve B-cells to GCBs and led us to hypothesize that the 
LCR plays a role in the transcriptional re-programming characterizing this stage of B-
cell differentiation. We utilized CRISPR-Cas9 technology, to knock out the LCR in 
mice, which resulted in complete abrogation of GC formation. Additionally, we found 
that this defect is GCB intrinsic, and the loss of the LCR does not affect other tissues 
that require BCL6. We also discovered that a single copy of the LCR, in cis with Bcl6, 
is sufficient for GCB formation. However, when the LCR is in trans with Bcl6 it 
results in the loss of GC formation. 
 
Furthermore, to study the effect of this LCR on gene regulation we tried to 
utilize an ex-vivo culture system that mimics aspects of B-cell differentiation into GC 
B-cells. These B-cell follicle cultures or GC ‘organoids’ were extensively utilized to 
grow and differentiate murine B-cells. During the course of this investigation, we 
optimized many aspects of the culture conditions. However, the ex-vivo system did 
not phenocopy the in-vivo observations made in LCR KO mice. Our current efforts 
are focused on identifying the necessary functional motifs within the LCR by utilizing 
lymphoma cell lines. 
 
This work adds to our current understanding of how chromatin architectural 
modulation may be controlled by critical loci around master transcription factors, 
thereby influencing widespread transcriptional regulation required for differentiation. 
Additionally, an understanding of this particular LCR upstream of Bcl6 has the 
potential to guide investigations into the manner in which chromosomal 
translocations—like the 3q27 translocations frequently observed in diffuse large B-cell 
lymphomas (DLBCL)—play a role in lymphomagenesis and the maintenance of such 
pathologies. 
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Chapter 1-A Brief History of Immunology 
   
1.1 Early theurgic understandings of immunity 
In 61 AD, the Roman poet Marcus Annaeus Lucanus started work on his 
unfinished epic ‘Pharsalia’ that tells the story of the civil war between Julius Caesar 
and the Roman senate forces led by Pompey. In book IX, after the assassination of 
Pompey, Cato the Younger embarks on a journey from Dyrrhachium to Utica, where 
he would make one last stand against Caesar (Ridley, 1905). Lucan describes an 
encounter with members of the Psyllian tribe who come to their aid during the perilous 
trek. Here, with some artistic liberties the great poet uses—arguably for the first 
time—the word ‘immunes’ to describe the famous resistance to snake venom that the 
tribe possessed. While Lucan has often been touted as an example of a great classical 
poet who stripped the role of the supernatural from historical events, here he 
succumbed to the allure of the magical powers of the Psyllian’s when he wrote  
 
“Of all who till the earth 
The Psyllians only are by snakes unharmed. 
Potent as herbs their song; safe is their blood, 
Nor gives admission to the poison germ 
E'en when the chant has ceased. Their home itself 
Placed in such venomous tract and serpent-thronged 
Gained them this vantage, and a truce with death…” 
 
Up until the 19th century, the term ‘immunitas’ and ‘immunis’, which were 
originally used in Latin legal texts to refer to ‘exempt status’, rarely ever alluded to 
incidents of resistance to poisons or plagues (Silverstein, 2009). However, the 
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observations were inevitably noted all along.  In describing the Plague of Justinian 
(spread of the plague described in figure 1.1), 541 AD, Procopius said  
 
“It started from the Aegyptians who dwell in Pelusium. Then it divided and moved in 
one direction…it spread over the whole world, always moving forward and travelling 
at times favourable to it…For it left neither island nor cave nor mountain ridge which 
had human inhabitants; and if it had passed by any land, either not affecting the men 
there or touching them in indifferent fashion, still at a later time it came back; then 
those who dwelt round about this land, whom formerly it had 'afflicted most sorely, it 
did not touch at all…” (Dewing, 1914). 
Figure 1.1 Possible origin and spread of the Justinian plague as described by 
Procopius (Keys, 2000) 
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 While curiosity around the phenomenon we refer to today, as ‘acquired 
immunity’ remained alive, another pertinent and related question was being tackled in 
parallel—what was the source of diseases? As one might guess, the earliest 
explanations were theurgic, i.e. the agency of divine or supernatural intervention was 
the source of all illness. In ancient Greece, Asclepius, the God of Medicine and 
healing was revered for centuries. Although Hippocrates (460-377 BC), the father of 
medicine, himself was considered to be a follower of Asclepius, he rejected the 
supernatural causations of ailments, and established empiricism, rational thought and 
science as virtues to be extolled in the search for explanations of disease (Savel & 
Munro, 2014). As is with family recipes passed down through generations that 
experience subtle evolution not through outright replacement but by the addition of 
newly acquired spices, the theurgic ideas made room for the Hippocratic tradition of 
medicine and slowly, and reluctantly (but never completely) gave way to western 
medicine. The blending of rational thought to a cogent belief in the power of the 
supernatural is the template of early medical prescriptions that can be found in 
historical texts of almost every culture around the world. The physicians and healers 
of the time walked the line between cautious prescription of strategies understood 
through observation and analysis, and explaining everything else with the help of the 
mood of Mother Nature, the alignments of stars, and when all else failed, the Gods.  
 
1.2 Early theories of immunity and disease   
 History does not speak of a watershed moment that may have cause a drastic 
paradigm shift. The Asclepius to Hippocrates transition had been gradual, and is 
arguably ongoing. However, mankind had found value in empiricism and the 
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philosophy of the Hippocratic school of thought caught on. An early theory from that 
period—pertinent to this discussion—advanced the idea that illnesses were a result of 
imbalances between the humors—blood (sanguine), phlegm (phlegmatic), yellow bile 
(choleric) and black bile (melancholic). These imbalances were initially thought to be 
in the actual amount of the humors. However, a ‘rediscovery’ of Hippocratic teachings 
by Galen (2nd century AD) along with a better understanding of physiology, anatomy, 
and pathology resulted in a shift in the paradigm from quantitative to qualitative 
imperfections of the humors. Between the 5th and 10th centuries AD, a gradually 
improving understanding of smallpox helped refine these early theories of disease. An 
illustrious Arab physician by the name of Rhazes, not only gave a thorough 
description of the clinical symptoms of smallpox but also put forward, possibly for the 
first time, a theory for ‘acquired immunity’ (even though he didn’t use these terms) 
(Abu Bekr Mohammad ibn Zakariya al-Razi, n.d.). In 1546, Girolamo Fracostoro, 
believed that small seeds (seminaria) were the cause of disease, that they spread from 
person to person, and had distinct tissue affinities. He also concluded that the 
differential affinities were the reason for ‘natural immunity’.  
 
 In the sixteenth and seventeenth centuries, two schools of medicine arose as a 
result of the scientific persuasions of physicists and chemists: iatrophysics—touting 
that all bodily functions have a mechanical characteristics; and iatrochemical—
whereby physiology was a product of chemical reactions. Most of the theories of 
acquired immunity were founded from the iatrochemical perspective (Silverstein, 
2009).   
 
 By the end of the seventeenth century, Western Europe had become seriously 
concerned with smallpox, and in 1714 the news of the eastern practice of variolation 
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had arrived in letters to the Royal Society of London that focused efforts on acquired 
immunity to the disease. These letters from Timoni and Pylarni, described the strategy 
of establishing a benign infection by inoculating pustule derived crusts from 
‘favorable’ cases of smallpox. What followed was the rapid popularity of this strategy 
that ultimately led to the first clinical trial in immunology—performed on a group of 
prisoners and another group of orphans in 1721. The success of these ‘Royal 
Experiments’ brought about renewed interest into the mechanisms of immunity 
facilitated by variolation. Around this time, the practice also spread to Colonial 
America thanks to the efforts of Cotton Mather who regularly read the Proceedings of 
the Royal Society of London, and learned of the letters from Timoni and Pylarni. 
Mather, with the help of other physicians spread the word via published documents 
from the New England region and addressed concerns that were raised in objections to 
the practice of inoculation (Figure 1.2). The text in the title page of the document 
reads “Some account of what is said of inoculating or transplanting the small pox /  by 
the learned Dr. Emanuel Timonius, and Jacobus Pylarinus ; with some remarks 
thereon ; to which are added, a few  in answer to the scruples of many about the 
lawfulness of this method ; published by Dr. Zabdiel Boylstone.” (Mather, 1721). 
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Figure 1.2 Title page from ‘Some account of what is said of inoculating or 
transplanting the small pox. Boston: Sold by S. Gerrish at his shop in Corn-Hill.’ 
(Mather, 1721) 
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One of the main theories of the time, explaining the acquired resistance to 
smallpox, was the Depletion Theory that suggested that the basis of this immunity was 
the depletion of a particular resource specifically required by the disease-causing 
agent. According to this view, the reintroduction of the causal agent or seed expedited 
the loss of said resource. Proponents of this theory included Thomas Fuller (Fuller, 
1730), James Kirkpatrick, Louis Pasteur (Pasteur L., Chamberland C., 1880), and even 
Paul Ehrlich who extended the idea to tumor immunity.  
 
 An inflection point in the history of disease and immunity came from the work 
of Louis Pasteur and Robert Koch. They provided experimental evidence for bacterial 
agents as the root cause for infectious diseases and a rubric for establishing them as 
such. Critical discoveries were made in the ten years from 1880, when Pasteur 
published his experiments on acquired immunity to fowl cholera via attenuated 
organisms (Pasteur, 1880), to 1890 when von Behring and Kitasato had discovered 
anti-toxins against diphtheria and tetanus (Behring & Kitasato, 1890). However, the 
investigators of the time ignored the role of the host in establishing the immunity, 
therefore producing a list of ‘passive theories’ as classified by Sauerback (Sauerbeck, 
1909). The time for ‘active theories’ was on the horizon and were bolstered by the 
discovery of the antibody and complement. 
 
1.3 Humoralists versus Cellularists 
Towards the end of the 19th century, there were two major debates within the 
field of immunology that split the scientists of the time in two factions. The first issue 
pertained to the role of inflammation—was it a physiological response that was 
ultimately beneficial to the organism or was it a deleterious side effect that contributed 
to the pathology of illness. The second debate, which was more of a battle, had to do 
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with the mechanisms that explained the basis of innate and acquired immunity—was it 
humoral or cellular.  
 
At the beginning of the debate there was a prevailing bias towards the humoral 
school of thought. After all, the history of the humors and their perceived role could be 
traced back to the early tradition of empirical medicine starting from Hippocrates.  
However, in 1858, Rudolph Virchow challenged the humoral basis of disease when he 
claimed that all pathology was a result of cellular malfunction and not that of 
maladjusted humors (Virchow, 1858). While his work gradually gained acceptance, 
the events that followed and the allegiances that scientists picked were peculiar. In the 
late 1870s, Robert Koch’s work on the etiology of wound infections further bolstered 
the germ theory of disease (Koch, 1876). In 1884, Ilya (Elie) Metchnikoff proposed 
the phagocytic theory (Metschnikoff & Freund, 1884), which initially, had more to do 
with the questions surrounding inflammation—a question that was primarily within 
the purview of pathologists. While this might make it seem that both Koch and 
Metchnikoff would have held similar ideas, you would be gravely mistaken in that 
assumption 
 
Metchnikoff, who was by training a zoologist, had an early interest in the 
digestive processes of invertebrates. While studying ‘mobile cells’ in starfish he 
formulated the idea that those cells could provide protection to the organism when 
challenged with a foreign, invasive object or organism. He performed a pilot 
experiment, in which he inserted a splinter into the starfish and then waited overnight 
to see how the mobile cells would respond. What he noticed was the cells 
(phagocytes) moving into the region of the injury. He postulated that the role was 
protective, and in that idea was the foundation of what would become the cellular 
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basis of inflammation. This was also the beginning of a protracted attack on his 
cellularist viewpoint which lasted decades. His early assertions from the platform of 
the phagocytic theory pertained to the nature of inflammation, which he claimed was 
not a deleterious response. This met with strong opposition from pathologists who 
viewed macrophages to be associated with purulent discharge and inflammation 
associated with poor prognoses. Such was the reaction to his ideas that Rudolph 
Virchow during a visit in 1883 cautioned Metchnikoff against advancing his theories 
at the time (Metchnikoff, 1921).  
  
 As one might imagine, the phagocytic theory had immunological implications 
and soon came under attack from the humoralists. The tale that followed is 
multilayered and complex and had serious implications for the trajectory of research in 
immunology. The debate that should have remained within the hallways of scientific 
discussion bled into political and nationalistic ideologies of the factions—the 
humoralists were primarily German and generally took their cues from Robert Koch, 
while the cellularists were mostly French who followed the lead of Metchnikoff 
(Silverstein, 2009).  A long held divide between the nations had come to a head during 
the Franco-Prussian war of 1870, which the French lost to the Germans, and led to 
beliefs and biases that compromised objectivity in the assessment of science.  
 
 Pasteur, who had received an honorary M.D. from the University of Bonn, 
returned the degree in the aftermath of the war. Ten years later, Koch and Pasteur 
engaged in an unpleasant debate over the etiology and pathogenesis of anthrax and 
other diseases, which eventually lost all sense of civility. This enmity between the two 
countries played out once again in the form of a scientific argument between Jules 
Bordet and Paul Ehrlich many years later (Zinnser, 1914).  
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 A number of observations came in quick succession in the last two decades of 
the 19th century from both sides, which in retrospect, hinted at the importance of both 
mechanisms. However, at the time, this possibility was forcibly overlooked and, in the 
end, the cellularists lost traction as a number of papers showing that cell-free fluids of 
normal and immunized animals could kill bacteria started surfacing. The humoralists 
held the view that the phagocytes that did show up were there to clean up debris and 
not actively involved in protective activities. The most important discovery that stalled 
the development of Metchnikoff’s ideas, was the discovery that antibodies conferred 
immunity against diphtheria and tetanus exotoxins (Behring & Kitasato, 1890). 
Another study showed that this serum could be passively transferred to another 
organism to confer protection against diphtheria without the involvement of any 
cellular components. This led Koch to proclaim the end of the phagocytic theory. 
Subsequent work from Paul Ehrlich showing the titration of anti-diphtheria antibodies 
(Ehrlich, 1897) emphasized the nature of antibodies as an entity that could be studied 
ex-vivo in the test tube—a convenience that immunologists readily found an affinity 
for—and heralded the age of antibody and complement research, a major step in the 
evolution of immunology, albeit at the cost of ignoring the cellular basis of immunity 
to the chagrin of many modern immunologists.  
 
 All that remained for the field to latch onto the idea of antibodies was a 
theoretical framework that could be the foundation of future work. To that extent, 
Ehrlich did not disappoint, and in a remarkable set of postulates, gave the world the 
idea of the side-chain theory. It should be added that the while the majority of the field 
shifted its focus to antibodies, there was an appreciation for the cellularist viewpoint 
for a number of reason including of course, legitimate curiosity around the phagocyte 
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theory but also in recognition of Metchnikoff as a relentless and brilliant scientist. 
This was reflected in the 1908 Nobel Prize that was jointly awarded to Metchnikoff 
and Ehrlich for their work on immunity (Nobelprize.org, 2014a).  
 
  From this point on, a relative hiatus in research surrounding cellularist ideas 
followed. Questions around delayed hypersensitivity (or bacterial allergy) were being 
half-heartedly addressed.  Landsteiner and Chase demonstrated the importance of 
mononuclear cells in cellular immunity in 1942 through their famous cell transfer 
experiments (Landsteiner & Chase, 1942) but these experiments amongst many others 
were coming late in terms of what was technically possible earlier in the 20th century. 
This half a century long lull was turned around in the 1960s when questions about 
allograft rejection, tolerance, viral infections, immune deficiencies and autoimmune 
diseases started surfacing.  
 
1.4 Early theories of antibody formation 
 The next step in the antibody story starts with the academic masses huddled 
around the new door that had just appeared—the question of where the antibodies 
came from and how were they made?  
 
On March 22, 1900, Paul Ehrlich, presented the “side-chain theory” in the 
Croonian lecture to the Royal Society of London. The theory, which later evolved into 
one of the foundational tenets of adaptive immunity, postulated that blood cells 
presented on their surface a variety of “side-chain receptors” that bound to 
toxic/infectious agents and inactivated them. He went on to suggest that the interaction 
between the foreign substance and the cell-bound receptor activated the cell, resulting 
in the large scale production and release of the receptor with the same specificity into 
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the blood stream of the organism. He further noted that the specificity of the receptor 
for the infectious agent was pre-determined (Ehrlich, 1900). An interesting 
observation about Ehrlich’s work has been made which suggests that a part of 
Ehrlich’s lay in the pictures he drew to convey his ideas. Figure 1.3 below is one of his 
illustrations depicting the side chain theory (Himmelweit, n.d.). 
Figure 1.3 Ehrlich’s side chain theory depicting the antibody-producing cell as having 
receptors for more than one type of antigen (black). Each antigen has a receptor with a 
different specificity. The antigen selects for increased production of the antibody. 
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The side-chain theory soon faced significant opposition by immunologists who 
believed in an instructional model of antibody production. According to these 
instructional theories, the antigen itself had a role to play in determining the specificity 
of the anti-toxin/antibody (Bordet, 1940). 
  
It wasn’t until the second half of the 20th century that selective theories re-
emerged. Eventually, the work of N. Jerne, D. Talmadge and F.M. Burnet resulted in 
the acceptance of the “clonal selection theory” as a paradigm for adaptive immunity 
(Goldsby, Kindt, Osborne, & Kuby, 2003). This theory confirmed most of Ehrlich’s 
predictions (with modifications), and in its current form states that the origin of the 
diverse repertoire of specific antibodies is independent of the antigen pool and each 
lymphocyte (both B and T cells) expresses only one kind of antigen receptor on its 
surface (Burnet, 1957). The antigen receptor diversity is attributed to a somatic gene 
rearrangement process that Burnet alluded to in 1957 when he proposed the clonal 
selection theory. According to him “The [clonal selection] theory requires at some 
stage in early embryonic development a genetic process for which there is no available 
precedence”. This speculative remark proved to be largely correct as was shown by a 
series of discoveries and the formal proposal of a somatic recombination process 
known as V(D)J recombination in 1976. 
 
  The history described thus far in this text has, for the sake of brevity, skipped 
over the minutia of the discoveries that were made up until the mid 1900s. However, a 
component of this story that may seem more pertinent are the cells of the immune 
system that we refer to as lymphocytes, and in the next section I will briefly recount 
the trajectory of work that was done that led to the discovery of lymphocytes, and the 
distinction that was made between T and B-cells.  
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1.5 The discovery of B and T lymphocytes 
 It is clear now that before the identification of lymphocytes, we had an 
understanding of the nature of the antibody, and its role in immunity had gradually 
been unravelled. It was in 1948, when Astrid Fagraeus showed that antibody 
formation correlated with the appearance of plasma cells in the spleen (Fagraeus, 
1948). The source of antibodies being plasma cells was subsequently confirmed via 
immunofluorescence microscopy (Coons, Leduc, & Connoly, 1955).  Antibodies had 
already been shown to be gamma globulins through electrophoretic studies (Tiselius & 
Kabat, 1939), and between 1952-1955, immunodeficient patients were identified as 
lacking gamma globulins (Bruton, 1952), and more specifically not having germinal-
centers and plasma cells (Good & Varco, 1955).  
 
 A curious observation of great implication was reported by Bruce Glick, when 
he showed that the removal of the bursa of fabricus from newly hatched chicks led to a 
defect in antibody formation. In retrospect, it is clear that the observation was initially 
overlooked, in part due to the publication of his work in Poultry Science, a journal of 
little consequence to immunologists (Glick, Chang, & Jaap, 1956). 
 
While the clonal selection theory was being proposed to the world, a better 
understanding of the composition of the antibody molecule was emerging—it was 
shown to possess 4 chains—paired heavy and light chains that were connected via 
disulphide bridges (Edelman, 1959; Porter, 1959). It was also shown that the heavy 
and light chains had a homogenous, crystallisable fragment (Fc) and a variable, non-
homogenous fragment (Fab). New questions about the genetic makeup of higher 
organisms and the manner in which the variable and constant regions could potentially 
arise in an antibody molecule were coming up and in 1965, Dreyer and Bennett 
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postulated that different variable and constant region genes could combine to make 
specific light chain or heavy chain of the antibody (Dreyer & Bennett, 1965).  
 
 The idea of the thymus as an organ critical for immune function had also been 
emerging. Jacques Miller noticed that thymectomized mice had severe 
immunodeficiencies. Independently, Good, who had studied agammaglobulinemia 
picked up clues from Glick’s work and combined them with the observations made in 
patients with thymoma. He also thymectomized mice and came up with similar defects 
in lymphocyte development. The observations made, initially projected the idea that 
the thymus gave rise to the cells that became lymphocytes and these populated various 
lymphoid tissues—the single lineage model. However, this model did not hold water 
as different phenotypes emerged from the removal of the bursa and the thymus. In 
1966, Max Cooper showed that the specific ablation of thymus in conjunction with 
whole body irradiation of chicks left them lymphopenic, with impaired cell mediated 
immunity and also had problems in their ability to reject grafts. These animals had 
lower antibody titers but still had plasma cells and formed germinal centers. On the 
other hand, when the bursa was removed along with whole body irradiation the 
inverse phenotype was observed (Cooper, Raymond, Peterson, South, & Good, 1966). 
This clarified the distinct roles of the two organs and also paved the way for the two-
lineage model—lymphocytes were B and T-cells.  
 
In 1974, a number of publications showed that the mammalian equivalent of 
the avian bursa of fabricus was the bone marrow (and fetal liver) (Owen, Cooper, & 
Raff, 1974; Ryser & Vassalli, 1974; Stocker, Osmond, & Nossal, 1974). In 1976, 
Susumu Tonegawa and Nobumichi Hozumi heralded the new era of immunology 
when they published their findings on the somatic rearrangement of variable and 
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constant genes in the process of forming an antibody light chain (Hozumi & 
Tonegawa, 1976), work for which Tonegawa was awarded the Nobel Prize in 1987 
(Nobelprize.org, 2014b). 
 
 The discovery of VDJ recombination by Tonegawa seems to be an appropriate 
place to conclude the historical introduction to the field of immunology. This is in part 
due to the idea that the discoveries made since the late 1970’s fall under the category 
of modern molecular immunology. While the subject matter of this thesis falls within 
the purview of epigenetic mechanisms involved in the regulation of gene expression 
between two specific stages of B-cell development, there is, yet again, a need for 
context around B-cell biology. To this extent, the next chapter will include 
descriptions of VDJ recombination and the manner in which it is tied to early B-cell 
development. I will then switch to the particular stage of B-cell development that is 
relevant to my graduate thesis work—Germinal Center B-cells. 
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Chapter 2: From the Bone Marrow to the Spleen and Things in Between 
 
2.1 Introduction 
 While the selective historical description of immunology and the critical early 
discoveries described in chapter 1 are unquestionably important, the subject matter of 
this thesis requires an introduction to a specific subset of information around B-cells. 
Research over the last 50 years has provided us an incredible amount of insight into 
the stages of B-cell development. As a student of immunology, I found B-cells to be a 
fascinating biological system to study as it forces us to reimagine the evolutionary 
pressures in a completely unconventional fashion.  
 
 It is generally accepted that most organisms have developed mechanisms to 
tackle insults to genomic DNA. These mechanisms range from prevention to repair 
modalities; and the manner in which these complex molecular systems came to be are 
intuitive as they rarely defy logic.  In the adaptive immune system, we have come to 
appreciate the jawed vertebrates to represent an evolutionary inflection point where 
lymphocytes first appeared (Pancer & Cooper, 2006). What makes the T and B-cells 
complete head turners are two distinct stages of somatic DNA alterations that 
challenge the ‘lets not mess with the genome’ wisdom: VDJ recombination and 
somatic hypermutation. Both of these processes coupled with class switch 
recombination involve manipulation of DNA in a manner, which requires precarious 
and dangerous regulatory processes that are now known to be associated with a 
number of pathologies including cancer.  
 
Among the many explanations surrounding the emergence of lymphocytes is 
the idea that the emergence of warm-blooded animals concurrently created the 
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evolutionary pressure of defense mechanisms against rapidly multiplying microbes 
that preferred warmer temperatures as well. The pressure, more specifically, required 
plasticity and diversity in its ability to respond. The development of this plasticity may 
have been preceded by the ability to simply employ phagocytic means of defense 
against microbes, a feature that is--assuming this hypothesis to be true—retained in B-
cells (Parra, Takizawa, & Sunyer, 2013).  
 
 While a definitive narrative of the events that led to the emergence of the 
lymphocytes will likely never be revealed, the research that addresses their biology is 
akin to unravelling a magical puzzle like no other. This chapter summarizes some of 
the key features of the molecular events that occur at the genetic and epigenetic level 
in B-cells as we understand them today. Towards the end I present the rationale behind 
my research that is described in subsequent chapters.  
 
2.2 Early stages of B-cell development and V(D)J recombination 
Collectively, the B-cell antigen receptor (immunoglobulin) repertoire enables 
the immune system to mount a protective response against a wide range of antigens. 
The immunoglobulin molecule or antibody is composed of 4 polypeptide chains: two 
identical light (L) chains and two identical heavy (H) chains that are held together by 
non-covalent bonds and covalent di-sulfide linkages. Each H and L chain can be sub-
divided into a constant (C) and a variable (V) region. The constant region is the 
determinant of the effector function for the particular antibody and can be one of five 
biochemically distinguishable immunoglobulin classes. The variable region of the 
heavy chain (VH) and the light chain (VL) fold together in the antibody molecule to 
form the antigen-binding site. The diversity in antigen recognition ability of antibodies 
is due to the variation in the amino acid sequence at the antigen-binding site. This 
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diversity is generated from a limited number of V region gene segment 
rearrangements resulting in the VH and VL portions of the heavy and light chains. 
  
The immunoglobulin heavy chain locus (Igh) in the mammalian genome is 
comprised of three discontinuous gene segments known as variable (VH), diversity 
(DH) and joining (JH) gene segments (Tonegawa, 1983). The number of genes in each 
segment vary between species, for example, in C57BL/6 mice, the Igh locus is on 
chromosome 12, is about 2.7Mb and contains 195 VH, 13 DH, 4 JH and 8 CH gene 
segments; whereas in humans the Igh locus is a 957 kb region on chromosome 14 and 
has 44 VH, 27 DH and 6 JH gene segments (Ebert et al., 2011; Matsuda et al., 1998). 
Figure 2.1 depicts the general organization of the Igh locus along with some of the 
epigenetic regulatory elements. 
Figure 2.1 A schematic of the organization of the Immunoglobulin heavy chain in 
mice (not to scale). The locus is ~ 3Mb in length with the VH gene segments 
occupying about 2.44Mb starting at the 5’ end of the locus (green shaded area). This 
region is further divided into distal (VHJ558 and VH3609), intermediate and proximal 
(VHQ52 and VH7183) families. The length of the different VH gene segment families 
is depicted. The intronic enhancer “iEµ” (between the JHs and Cµ segment) and the 
promoter upstream of DQ52 (PQ52) are shown as yellow circles. The remaining 
constant regions are represented in the blue shaded area along with the 3’ regulatory 
region shown as a yellow oval. 
 
The immunoglobulin light chain locus (Igl) differs from the Igh locus in that it 
does not have a diversity gene segment and the recombination is only between the VL 
and JL gene segments (Bernard, Hozumi, & Tonegawa, 1978; Early, Huang, Davis, 
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Calame, & Hood, 1980). The light chain itself is of two kinds: kappa and lambda, and 
their recombination does not occur during the pro-B cell stage. Instead, Igl locus VJ 
recombination occurs in the small-pre-B cell stage when the Igh recombination has 
been completed. The mechanism of recombination of the Igl locus is similar to that of 
the Igh locus (Murphy, 2011). 
 
The process of recombination of the gene segments is guided through 
recombination signal sequences (RSS) that are recognized by V(D)J recombinase 
enzymes known as RAG-1 and RAG-2. These enzymes bind to the RSS that flank 
gene segments to be recombined and subsequently align them next to each other 
(McBlane et al., 1995). The RAG-1/RAG-2 complex then cuts a single strand of both 
DNA backbones between the RSS and the coding region creating two hairpin 
structures.  The cells non-homologous end joining (NHEJ) DNA repair proteins (like 
Artemis, Ku70:Ku80 heterodimer, XRCC4, DNA ligase IV and DNA Protein Kinase) 
help in resolving the hairpin structure. This leaves the two gene segments recombined 
and cleaves out the intermediate DNA to form the extra-chromosomal circular DNA 
known as the signal joint.   
 
The RSS can come in two different flavours and the basic construction 
includes a conserved seven nucleotide sequence  (5’CACAGTG3’) contiguous with 
the gene segment coding region, followed by either a 12 or a 23 bp non-conserved 
spacer region, finally followed by another conserved block of nine nucleotides 
(5’ACAAAAACC3’). A gene segment flanked by an RSS with the 12-bp spacer can 
only combine with another gene segment with an RSS that has a 23-bp spacer. This is 
known as the 12/23 rule (Eastman, Leu, & Schatz, 1996; Van Gent, Ramsden, & 
Gellert, 1996). 
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The sequence of gene rearrangements of the Igh locus during the pro-B cell 
stage is DH to JH resulting in the DJH followed by VH to DJH. The sequential gene 
rearrangement is achieved in part, by the specific arrangement of RSS in the Igh locus: 
the VH and JH segments are all flanked by the 23-bp RSS motifs whereas the DH gene 
segments are flanked on both sides by the 12-bp RSS. The 12/23-rule ensures that one 
DH gene segment recombines with another JH segment first to form DJH, and the 
second recombination occurs between a VH segment and the DJH segment (Murphy, 
2011). V(D)J recombination is now known to be a highly regulated process that is not 
only important for the generation of the diverse repertoire of antibodies but also for its 
role in lineage specification of B-cells.  
 
One of the hallmarks of a B-cell is its antigen receptor with unique antigen 
specificity. The fate of the B-cell is intricately tied to the assembly of a viable antigen 
receptor. B cells undergo most of their development in the bone marrow, and V(D)J 
recombination of the Immunoglobulin heavy chain locus occurs during the early 
stages of the differentiation process followed by the recombination of the light chain 
locus in a highly ordered and regulated manner (Figure 2.2). Built into these systems 
are backup plans and error fixing opportunities that are also summarized below.  
 
Figure 2.2 B-cell development from lymphoid progenitors to mature B cells depicting 
the sequential recombination of Ig genes during VDJ recombination. 
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 Lymphopoiesis starts in the bone marrow of adult mammals, where a 
hematopoietic stem cell (HSC) interacts with bone marrow stromal cells to give rise to 
a common lymphoid progenitor (cLP). The cLP can have many different fates, one of 
which is the formation of an early-pro-B cell. This stage is marked by the initiation of 
Igh rearrangements, specifically the recombination of DH to JH on both alleles. The 
early pro-B cell stage is characterized by a high expression of CD117 (kit), CD24low 
and a lack of CD25 on the surface (Murphy, 2011).  
 
Once the DH to JH recombination is complete, the cell moves to the late-pro-B 
cell stage. The Igh locus V(D)J recombination is completed during this stage. VH to 
DJH recombination is attempted on one of the alleles, and if an intact µ-heavy chain 
mRNA is produced, V(D)J recombination stops and the cell transitions into a large 
pre-B cell. This transition is marked by the surface expression of a pre-B cell receptor, 
which is Igµ protein along with two surrogate light chains. Pre-B cell receptor 
signalling is known to prevent the second allele from undergoing V(D)J 
recombination—also known as allelic exclusion—through Ca2+-Calmodulin mediated 
binding of the E2A transcription factor. This inhibitory interaction results in the down-
regulation of components of the recombination machinery (Hauser, Grundström, & 
Grundström, 2014). If the initial V(D)J recombination does not produce a µ chain the 
cell makes another attempt on the other allele. If the second attempt fails as well the 
cell undergoes apoptosis. 
After the expression of the pre-B cell receptor, the late-pro-B cell starts proliferating 
and the cells are now referred to as large-pre-B cell stage. Rag1/2 expression is 
significantly reduced during this stage, as there is no further recombination at any of 
the immunoglobulin loci. Once proliferation stops, the cells become small-pre-B cells 
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and the recombination of the VL and JL of the Igl begins. After the completion of the 
light chain recombination, both the heavy and the light chain are expressed as surface 
IgM molecules and the cell becomes an immature-B cell. B cells with self-reactive 
IgM molecules are negatively selected in the bone marrow at this stage while the 
surviving B cells leave the bone marrow to become mature-B cells (Jung & Alt, 2004).  
 
 As mouse models are used extensively to study the immune response, it is 
important to point out that B-cell development is remarkably similar in humans and 
mice. A schematic with an overview of the major stages of B-cell development is 
shown in figure 2.3. 
Figure 2.3 Major stages of B-cell development to the formation of Memory B-cells 
and Plasma Cells. 
 
 In both species, B-cells originate from fetal liver (B-1) and bone marrow (B-2) 
(Nuñez et al., 1996). The underlying molecular mechanisms that lead to the expression 
of the BCRs are similar between mice and humans (LeBien, 2000). Of note is one 
distinction during the pre and pro-B-cell stages. While in mice the differentiation and 
survival of the early B-cells is dependent on IL-7, human B-cells do not show any 
dependency on IL-7 (Namen et al., 1988; Noguchi et al., 1993; Prieyl & LeBien, 1996; 
Puel, Ziegler, Buckley, & Leonard, 1998). Over the last few decades, extensive 
research has led to the discovery of a number of differentially expressed surface 
markers that can be utilized to distinguish different B-cell compartments. While these 
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markers are analogous between the two species, there are occasional differences in 
expression (and sometimes nomenclature). Here on, the markers mentioned will 
pertain to mice.  
 
 Once an IgM expressing immature B-cells are formed they exit the bone 
marrow and are referred to as transitional B-cells. These cells can be subcategorized as 
T1, T2 or T3 cells based on their different surface marker profiles and functions 
(Allman et al., 2001; Carsetti, Köhler, & Lamers, 1995; Loder et al., 1999). 
Transitional B-cells do not enter the lymphatics and are confined to circulation in the 
blood and spleen. These cells have two potential fates as they further differentiate: 
Follicular B-cells (FOB) or Marginal Zone B-cells (MZB) (Pillai & Cariappa, 2009). 
These two cell types have distinct functions, localize to specific and separate niches, 
and even though they both have BCRs, display different signalling outcomes. The 
mechanisms that are involved in these two separate fates are not completely 
understood. MZBs (IgMhi, IgDlo, CD21hi, CD23lo) localize to the marginal zone of the 
spleen and can act in a T-cell independent fashion to offer a first wave of defense 
against blood borne pathogens (Balazs, Martin, Zhou, & Kearney, 2002). T-
independent antigen responses also fall under the purview of B-1 cells which will not 
be discussed in this work. FOBs (IgMlo, IgDhi, CD21lo, CD23hi) are the lineage of cells 
arising from transitional B-cells that are involved in T-dependent antigens. The T-cell 
dependence is explained with the help of the two-signal model of the humoral immune 
response (Bretscher & Cohn, 1970). Signal 1 is the antigen binding to the BCR, while 
signal 2 is the ‘help’ that is offered to the B-cells after they internalize the antigen, 
process them into smaller fragments, and subsequently present them on the cell 
surface to either CD4+ T-cells, thereby following the T-dependent response. On the 
other hand, T-independent responses involve the interaction of innate immune cells 
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with B-cells for signal 2. T-dependent responses lead to a response that lasts longer 
and results in a profound increase in the affinity of the BCR for its cognate antigen. 
 
 The FOB-cells are the freely recirculating B-cells in the peripheral immune 
system. These ‘mature’ B-cells are referred to as ‘follicular’ as they are found in 
organized aggregates within secondary lymph organs (white pulp of spleen and 
cortical regions of lymph nodes) known as primary B-cell follicles (labelled ‘F’ in 
Figure 2.4, left panel). Within these follicles exist a complex network of stromal cells 
known as follicular dendritic cells (FDCs) interspersed with tangible body 
macrophages and T-follicular helper cells (Figure 2.4, right panel). FDCs produce the 
chemokine CXCL13 (Vermi et al., 2008) and attract CXCR5 expressing B and T-cells 
to organize the follicular structure (Ansel et al., 2000). FDCs also express IL-6 and 
BAFF which are important for the survival of GCBs, as well as adhesion molecules 
that are required for interactions with the B-cells in the follicle. Upon activation with 
antigen the B-cells will put in motion the process that leads to the formation of the 
germinal center.  
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Figure 2.4 (LEFT) Cross-section of spleen from 8-week old C57BL/6 mouse. B-cells 
in brown (anti-B220), T-cells in blue (anti-CD3), and B-cell follicles are dark brown 
due to a high density of FOBs. Marginal Zone (MZ), Red Pulp (RP), Bridging Zone 
(BZ) are also indicated. (RIGHT) Cross-section of a mouse spleen showing follicular 
dendritic cells in dark blue (anti-CD35) within individual B cell follicles stained 
brown (anti-IgD). The position of the adjacent T zones and surrounding red pulp are 
labeled for clarity. The spleen is from an un-immunized mouse and the follicles lack 
GCs, and are thus primary follicles. Image is from the open source ‘Immunology 
Image Resource’. The sections were submitted by Xiaoming Wang and Jason Cyster. 
Howard Hughes Medical Institute and Department of Microbiology and Immunology, 
UCSF. 
 
2.3 Cells and functions of the Germinal Center 
The T-dependent response is similar to the T-independent in that a few days 
after the initial antigenic challenge, appear plasma cells in the extra-follicular regions 
of the spleen. These express low affinity IgM just like that of the T-independent 
response. However, around that time an entirely different and complex sequence of 
events starts in parallel. T-cells in the spleen that have been independently activated 
by antigen interact with activated B-cells for the same antigen. The site of this 
interaction is the border of the follicle adjacent to the T-cell zone known as the T:B 
border (Jacob, Kassir, & Kelsoe, 1991; Nieuwenhuis & Opstelten, 1984). Here, the 
processed antigen is expressed on the activated B-cell with MHC II complex for the 
CD4+ T-cells to recognize via their TCRs. The B-cells expressing B7-1(CD80) and 
B7-2 (CD86) interact with CD28 on the T-cells. This leads to bi-directional activation 
signals that facilitate proliferation of T-cells and the B-cells (Coffey, Alabyev, & 
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Manser, 2009; Garside et al., 1998; Okada et al., 2005). In addition to these signals, 
the T-cells now start expressing CD40L (CD154) which binds to CD40 on the B-cells. 
This interaction leads to downstream signalling which results in the transcription of 
immunoglobulin genes and class-switching from IgM/IgD to IgG. Secreted cytokines 
dictate the specific type of class switching that occurs. A cluster of rapidly 
proliferating B-cells will start forming from the T:B border which organizes itself into 
a dark zone (DZ) and a light zone (LZ). Figure 2.5 shows a secondary follicle in a 
tonsillar section stained for Ki-67, the region the GC with a denser population of cells 
at the bottom is the DZ while the sparsely stained (non-proliferating region) is the LZ. 
Figure 2.5 Secondary follicle in zoomed in cross section of tonsillar tissue stained 
with Ki67. Image reproduced from Pathologyoutlines.com. 
 The DZ is primarily occupied by the dividing B-cells known as centroblasts 
that are CXCR4hi(Allen et al., 2004). The stroma of the DZ consists of CXCL12 
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(ligand for CXCR4) expressing reticular cells (CRCs).  The CXCL12 gradient retains 
the centroblasts in the DZ, away from the LZ that is rich in FDCs (Bannard et al., 
2013; Rodda, Bannard, Ludewig, Nagasawa, & Cyster, 2015). Centroblasts have 
higher levels of AID and therefore are believed to be the site of somatic hypermutation 
(SHM), through which clonal variants of different affinities for antigen are formed 
(Muramatsu et al., 2000). Variants with higher affinity for antigen are selected 
whereas the ones with lower affinities lose the selective competition and die out. The 
LZ is posited to be the site of this selection. The overall organization of the LZ is less 
compact but more diverse—in addition to the FDCs it also has T-follicular helper cells 
(TFH-cells) and infiltrating naïve B-cells. The B-cells migrating from the DZ into the 
LZ are subsequently known as centrocytes. Extensive research has shown that affinity 
maturation is a result of an iterative process of SHM (in DZ) and selection (in LZ) 
over multiple cycles. B-cells with improving affinity for antigen can return to the DZ 
for another round of SHM to further improve their ability to recognize and neutralize 
an antigen (Allen, Okada, Tang, & Cyster, 2007; Gitlin, Shulman, & Nussenzweig, 
2014; Schwickert et al., 2007; Victora et al., 2010). TFH-cells in the LZ play a critical 
role in the positive selection process by providing proliferative signals and driving the 
fate of the GCB towards plasma cells (Allen et al., 2007; Meyer-Hermann, Maini, & 
Iber, 2006; Victora et al., 2010). 
 
The fate of the GCB depends on the manner in which the affinity for antigen is 
modulated. Changes that potentially create affinity for self-antigens result in negative 
selection in addition to the ones where the affinity is decreased for antigen. Positively 
selected cells have two potential fates—they can either become antibody secreting 
plasma cells (PC) or long-lasting memory B-cells (memB). While the mechanisms that 
dictate the fate-decisions are not completely understood (and is currently somewhat 
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confusing), there are a few clues about the signals that correlate with one fate or 
another. A temporal hypothesis claims that the propensity of the B-cell to become a 
PC increases as the BCR affinity for the antigen increases, while the memB-cells arise 
from early GC phases (Weisel, Zuccarino-Catania, Chikina, & Shlomchik, 2016). 
 
2.4 BCL6-the master regulator of Germinal Center B-cells.  
 A simplified version of the events that occur during the transition of an 
antigenically naïve B-cell (FOB) to GCB is shown in figure 2.6.  
Figure 2.6 Schematic depicting transition from naïve B-cell to GCB-cells. The 
schematic also shows the T:B cell interaction priot to the formation of Germinal 
Centers and the interaction if GCBs with Follicular dendritic and Follicular T-helper 
cells.  
 
 A foundational concept in developmental biology is that differentiation is 
brought about through changes in gene expression. A cell transitioning from cell stage 
X to stage Y will exhibit a profound shift in the type and level of genes expressed. The 
	 35	
regulatory mechanisms involved in the transcriptional changes associated with such 
transitions have been a subject of interest for decades. With the advent of next-gen 
sequencing technologies, there has been an influx of information pertaining to the 
overall gene expression profiles that characterize different cells in eukaryotic 
organisms. A concept that emerged in in the late 70’s provides insight into one of the 
key aspects of this regulation—it is the idea of the master regulator or master 
transcription factor. The existence of such a modality was first hypothesized to be 
involved in sex determination (Ohno, 1979). The concept was subsequently extended 
to cell specification in drosophila and plants. Chan and Kyba, noticing an upswing in 
the use of this term proposed the following criteria for the definition of a gene that 
would be classified as a master regulator, “a gene that is expressed at the inception of 
a developmental lineage… participates in the specification of that lineage by 
regulating multiple downstream genes … and critically, when misexpressed, has the 
ability to re-specify the fate of cells destined to form other lineages.” (Chan & Kyba, 
2013).  
 
 In line with this definition is the gene BCL6, which is now an accepted master 
transcription factor of GCBs. Basal level of BCL6 transcripts and protein are present 
in the naïve B-cell stage, and the expression is upregulated many fold at the inception 
of the germinal center (Figure 3.3). BCL6 was originally discovered in 1993 as the 
gene that was associated with the t(3;14)(q27;q32) and t(3;22)(q27;q11) chromosomal 
translocations frequently observed in B-cell lymphomas—primarily DLBCL (Baron et 
al., 1993; Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS et al., 
1993). This translocation is reported to be present in 20-35% DLBCL cases and is 
associated with the deregulated expression of BCL6.  
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BCL6 is a 95 KDa nuclear phosphoprotein primarily works as a transcriptional 
repressor. It belongs to the BTB/POZ/ZF family with the BTB/POZ domain at the N 
terminal, the Zinc fingers at the C terminal and PEST domains in between the two 
regions. The BTB domain dimerization is known to be a feature of proteins that 
possess these domains, and this implies that BCL6 itself must function as a dimer. 
Binding of BCL6 to DNA is via the ZF domains, whereas the BTB/POZ and PEST 
domains are involved in the actual repressive activities. The repression is achieved via 
direct or indirect recruitment of histone deacetylases (HDACs). The indirect 
recruitment is through corepressor complexes like NCOR2 (SMRT), NCOR1, BCOR, 
MTA3, and CTBP1. The BTB/POZ domains are known to recruit the NCORs, BCOR 
and CTBP1 whereas the central PEST domains recruit MTA3 (and CTBP1). The 
binding of BCL6 directly to the promoter DNA is usually a requirement for activity 
but recruiters of BCL6 like ZBTB17 (Miz1) have also been reported (Basso & Dalla-
Favera, 2010) 
 
The repressive function of BCL6 is essential for the formation of germinal 
centers, as the GCB cell experiencing genotoxic stress during the process of SHM 
would otherwise succumb to DNA-damage-induced apoptosis. Some of the genes 
repressed by BCL6 include TP53 (R. T. Phan & Dalla-Favera, 2004), CDKN1A (R. 
Phan, Saito, Basso, Niu, & Dalla-Favera, 2005), ATR (Stella Maris Ranuncolo et al., 
2007) and CHEK1 (Stella M. Ranuncolo, Polo, & Melnick, 2008). In addition to the 
repression of the DNA-damage response genes, BCL6 also regulates the expression of 
genes involved in apoptosis. BCL2, an anti-apoptotic protein, is suppressed by the 
action of BCL6 (Ci et al., 2009; Saito et al., 2009). On one hand, the suppression of an 
anti-apoptotic molecule may seem counterintuitive, but it makes sense when the 
elimination of sub-par GCBs (the ones that need to be negatively selected due to 
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inefficient engagement of BCR to antigen or reactivity to self antigens) is of utmost 
importance. Furthermore, BCL6 targets also include genes that would otherwise 
regulate the differentiation of GCBs. A key gene involved in this is PRDM1 (gene 
encoding Blimp-1) which is itself a master regulator of plasmacytic differentiation 
(Tunyaplin et al., 2004). 
 
Therefore, the actions of BCL6 represent a complex network of phenotypes 
maintained in a delicate balance. When this balance is disrupted through deregulation 
of BCL6, then as predicted by Chan and Kyba, there is a ‘respecification of fate’ in 
that they lead to various B-cell lymphomas (primarily DLBCL and occasionally FL).   
 
2.5 Genomic remodeling during the NB to GCB transition. 
 As mentioned earlier, the differentiation of NB to GCB is accompanied by a 
profound shift in the type and level of the genes that are expressed. The underlying 
regulatory modalities that enact such transitions are not completely understood and are 
a subject of widespread research spanning different cell systems. Over the last decade, 
epigenetic regulatory mechanisms influencing coordinate and rapid gene expression 
changes have been shown to be critical for differentiation. This is especially important 
in the large scale changes seen in multicellular organisms (Cantone & Fisher, 2013; 
Natoli, 2010; Spitz & Furlong, 2012). This makes intuitive sense when we come to 
appreciate the complexity of the genome of higher organisms. To efficiently and 
consistently coordinate thousands of genes, spread across distinct chromosomes, so 
that they simultaneously undergo transcription at physiologically relevant levels 
requires a number of strategies that directly involve the genome to be spatially and 
qualitatively modified. While individual genes can be regulated through epigenetic 
mechanisms like DNA methylation or histone modifications (Zhou, Goren, & 
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Bernstein, 2011), another aspect of regulation involving the folding and looping of the 
genome is gaining significant attention.  
 
Chromosomal conformation capture technologies and DNA-fluorescence in-
situ hybridization (FISH) have given us a view into these 3D reorganizations that 
occur during different stages of differentiation (Bickmore & Van Steensel, 2013; 
Cavalli & Misteli, 2013; Fabre et al., 2015). A number of studies have also shown that 
the genome itself is compartmentalized in specific and recurrent ways to control gene 
expression in organisms (Baú et al., 2011; Dixon et al., 2012, 2015; Lieberman-aiden 
et al., 2009; Sanyal, Lajoie, Jain, & Dekker, 2012; Sexton et al., 2012; Sexton & 
Cavalli, 2015)    
Figure 2.7 Transcriptional changes during germinal center B cell differentiation from 
RNA-seq on human tonsillar NB and GCB. 
 
Published work from our group (Bunting et al., 2016) describes in immense 
detail the epigenetic and genetic changes that potentially regulate gene expression 
changes between NB and GCBs. In humans there are approximately 1800 genes that 
are differentially expressed (Figure 2.7). This change is accompanied by a 
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decompaction of the genome, increase in promoter-promoter interactions, 
reorganization of enhancer networks, 5’ to 3’ looping of actively transcribed genes, 
and the remodeling of gene neighborhoods which are small looping clusters of genes 
and their regulatory elements.  
 
Figure 2.8 UCSC Browser view of normalized Hi-C counts in the 3q27 locus between 
human NB (blue) and GCB (orange). Significant enrichment of contacts is observed 
around the BCL6 locus in GCBs compared to NB-cells. 
 
The general decompaction of the genome can be thought of as an early step in 
the transition from NB to GCB. This decompaction has been captured through genome 
wide chromosomal conformation capture (Hi-C) studies in our lab on human tonsillar 
NBs (IgD+ CD38lo) and GCBs (CD77+ CD38hi). The loosening of the chromosomes 
is reflected in the Hi-C data as interactions between the p and q arm of chromosomes 
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are lost, and the nuclei become larger. Figure 2.8 is a browser view of the Hi-C data 
for the 3q27 locus in humans (which is the location of BCL6) where we can see a 
substantially higher level of chromatin interaction in GCBs as compared to NBs. This 
specific observation is an important clue in our subsequent studies as the locus coding 
for the GCB master regulator maybe doing much more than just coding for an 
influential transcriptional repressor. 
  
 An increase in promoter-promoter interactivity was observed on performing a 
gene centered analysis of the Hi-C data. Our understanding of active, poised and 
inactive regions of chromatin relies on the identification of associated histone 
modifications. To this extent, there are modifications of lysine-4 (K4) and lysine 27 
(K27) of histone 3 (H3) which can be determined via ChIP-seq for these different 
marks. Active promoters are H3K4me3+, H3K27Ac+ and are bound to the histone 
acetyl-transferase P300 and RNA polymerase II (PolII) (spicuglia & Vanhille, 2012). 
These can also be H3K4me2+. Inactive chromatin is associated with H3K27me3 
modifications. Our analysis showed that highly interactive promoters were associated 
with BCL6, MTA3, LMO2, BCL7A, BCR signaling pathway, TEC, PIK3CG and 
CAM2KB. The highly interactive promoters were enriched for active chromatin marks, 
had higher levels of transcription in GCBs vs NBs. The strongest promoters in GCB 
were bound by P300, PU.1, SpiB and IRF8. These promoters usually had significantly 
lower interactivity in NB-cells. Importantly, the genes with highly interactive 
promoters were also actively transcribing genes that drive the GCB-cell phenotype.  
 
Cell type specific gene expression is coordinated in large part by the action of 
enhancers. Enhancers are H3K4me2+ and H3K4me3-. Active enhancers can be 
differentiated from poised enhancers through the presence of H3K27Ac marks 
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(Creyghton et al., 2010). It should be noted that P300 is bound to both Enhancers and 
promoters. H3K4me1 is associated more with enhancers than promoters. H3K4me2 is 
a mark that is more or less equitably laid down in enhancers and promoters whereas, 
H3K4me3 is a sign off active promoters more than it is of active enhancers (spicuglia 
& Vanhille, 2012). Another point that should be made is that the terms ‘open’ and 
closed’ chromatin, while in common use, are less precise in their implications as open 
chromatin could be poised or active. The combinations of various histone 
modifications, transcription factor and chromatin modifier binding profiles create a 
somewhat complex network of chromatin states, therefore, here on the usage of ‘open’ 
and ‘closed’ chromatin in this text will be minimal. 
 
As should be obvious, both NB and GCB have their specific and overlapping 
sets of enhancers. Our lab identified 5167 enhancers (<50Kb away from genes) of 
which 2818 were unique to NBs. Enhancers working in NB were largely involved in 
immune homeostasis functions. On the other hand, GCBs have 5339 enhancers 
(<50Kb away from genes) of which 2990 are unique. These contact GCB 
differentiation genes, cell proliferation genes, and GCB-type DLBCL genes including 
BCL6, CKS2, MCM2, MCM5, RFC3, SPRED2, PRC1 and TIAM2. Generally, 
enhancer-enhancer and enhancer-promoter interactions were markedly increased in 
GCBs vs NBs. However, this increase was not random as interactions between non-
regulatory loci did not increase as a by-product of looser chromatin. This brings home 
the point that the changes described thus far are relevant to the reprogramming of 
transcriptional networks specific to GCBs. When looking for genes that had the 
highest promoter-enhancer interactions we discovered a set of 32 genes, 90% of which 
are upregulated and relevant in GCBs.  Some of these genes include BCL6, CKS2, 
DGKG, ETV5, PVT1, SERPINA9, and SPP1.  
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Figure 2.9 UCSC Genome Browser tracks in NB and GCB showing chromatin marks 
and locations of 3C primers (arrows) across a region upstream of BCL6. The red 
arrow denotes the anchor point for all 3C PCRs. Bar plots show the mean 3C 
enrichment in NB and GCB, 3C DNA templates (n = 3) at the 
regions indicated. Primer pairs were averaged across each region. Performed a one-
tailed, unpaired t-test (**p < 0.05; *p < 0.1). 
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 To validate the interactions between upstream enhancers and promoters for the 
set of 32 genes the BCL6 locus was chosen for 3C studies. The browser image in 
figure 2.9 shows ChIP-seq tracks with called peaks for H3K27Ac, H3K4me2 and 
H3K4me3 to define the promoter and enhancer regions upstream of BCL6. The 
enhancers positioned ~100-400 Kb upstream showed significantly higher interactions 
with the BCL6 proximal promoter as compared to the inter and intragenic loci 
characterized by low levels of enhancer marks. Therefore, the data suggests an 
association of this reorganization of enhancer networks with the GCB transcriptional 
profile. Interestingly, this further promotes the idea that the chromatin around the 
BCL6 gene has enhancers that may be characterized as locus control regions as they 
might be involved in a critical control step for the overall transcriptional 
reprogramming and not just the nearby genes.  
Figure 2.10 Schematic of merging gene neighborhoods into gene cities. 
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Further utilization of the Hi-C data also revealed groups of genes separated 
into boundary-delimited (or insulated) neighborhoods. These gene neighborhoods, 
previously described to be highly conserved between species which speaks to their 
potential role in gene regulation (Dixon et al., 2012; Vietri Rudan et al., 2015). Genes 
within such neighborhoods are usually expressed in a coordinated fashion and the 
boundaries are defined by CTCF binding. We noticed a similar pattern of expression, 
epigenetic marks, and significantly higher levels of chromatin interactions in the gene 
neighborhoods of GCB and NB cells. An interesting observation was the merging of 
these clusters into larger domains described as ‘gene cities.’  
 
This merging occurred from the NB to the GC stage and is accompanied by a 
coordination of expression of the genes from the original clusters. Furthermore, the de 
novo acquisition of the epigenetic mark H3K4me3 was also noticed between the 
groups of genes that were initially in distinct neighborhoods in NB. Again, the genes 
that fell into the category of merged gene cities were highly representative of gene sets 
involved in the GCB phenotype including proliferation, MHC Class II-mediated 
antigen presentation, and metabolic stress. They also have hypo-methylated promoters 
in GCBs compared to NBs.  
 
The pattern emerging from the observations made thus far is that there is a 
deliberate attempt to modify the architecture of the genome that allows for 
coordination of gene expression relevant to the NB -GCB transition. Genes that are 
isolated and regulated independently in NB are brought physically closer together for 
better coordination and co-regulation of those genes in GCBs. The multiple levels of 
physical reorganization around BCL6 is interesting as it highlights an evolutionary 
pressure that results in clustering of genomic loci that are not only coding for critical 
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master regulators important for differentiation but also physically playing a role in the 
reorganization of other loci for regulatory purposes.  
Figure 2.11 2D heat-maps of normalized interaction frequencies in NB and GCB cells 
and log2 gene expression ratio (GCB/NB) across a chromosome 3 region. 3D gene 
neighborhoods in NB and GCB cells are indicated (blue and orange triangles, 
respectively). Gene expression ratios between GCB versus NB cells determined by 
RNA-seq is shown below, along with location of each gene. 
 
To further explore the interactome of BCL6, 4C-seq was performed in NB and 
GCBs. With 4C bait primers in the BCL6 promoter, approximately 3000 intra-
chromosomal interactions were noted to be significantly gained in GCB vs NB (Figure 
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2.12). The majority of these gained interactions were within the merged gene city with 
BCL6 (Figure 2.11). Another set of gained interactions that were of interest were again 
in the distal enhancers (two distinct enhancers) captured earlier via 3C, upstream of 
BCL6.  
Figure 2.12 Genome visualization tracks showing H3K4me3, H3K4me2, and 
H3K27Ac histone modification peaks, normalized Hi-C interaction frequencies 
(merged), and normalized read counts of 4C contacts made with the BCL6 gene 
promoter in NB and GCB across the	BCL6 gene region on chromosome 3. 
 
This cluster of enhancers—which gained interactions with the BCL6 promoter 
in GCB/NB—was collectively categorized as one putative locus control region (LCR). 
We hypothesized that this LCR might play an important role in regulating BCL6 and 
other GC specific genes, and thereby would be required for GC formation.  
 
Furthermore, when the 4C bait was anchored within the putative LCR itself, 
we observed significant interactions with the BCL6 promoter (Figure 2.13).  This 
further solidified our belief that the putative LCR was a regulatory hotspot involved in 
regulating GC physiology. This regulation could be due to direct contacts made with 
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both nearby and distant genes so as to pull them closer in proximity and thereby co-
regulate their expression. Other potential mechanisms could involve a higher order 
function where the overall reorganization of the genome (centered around the BCL6 
locus) requires binding of multiple transcription factors and chromatin modifiers.  
Figure 2.13 Top: plot showing locations of BCL6 LCR contacts made in GCB vs NB 
detected by 4C-seq across chromosome 3 (p < 0.05, Fisher’s exact test). Bottom: 
zoomed-in view of BCL6 and LCR showing histone modifications and normalized 
read counts of contacts made with the putative BCL6 LCR detected by 4C-seq in NB 
and GCB. 
 
 Analysis of the GCB specific enhancers defined by H3K27Ac and H3K4me2 
enrichment in GCBs compared to NBs, we also found that a highly significant 
proportion of these enhancers also overlapped with the loci that increased contacts 
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with the putative LCR. A representation of this analysis is shown through a circus plot 
depicting the entire human chromosome 3, with H3K4me2 peaks in green, H3K27Ac 
peaks in red and the GCB specific enhancers overlapping 4C contacts with the 
putative LCR in blue (Figure 2.14). Additionally, an analysis of the genes most 
proximal to these enhancers, we discover that they include GC differentiation 
signature genes (lower panel of Figure 2.14). 
Figure 2.14 Top: Circos plot showing chromosomal locations of the enhancer-
enhancer contacts made between the putative BCL6 LCR (4C anchor in putative LCR) 
and other GCB specific enhancers in GCBs (but not in NB), as detected by 4C-seq 
across chromosome 3 (p<0.05, Fisher’s exact test). The outermost ring of the plot is an 
ideogram of chromosome 3. The green and red peaks depict regions of enrichment in 
GCBs for H3K4me2 and H3K27Ac respectively.  Bottom: Gene set enrichment and 
depletion among genes near GC B cell-specific enhancers that form contacts with the 
putative GC B cell-specific LCR upstream of BCL6 in GC B cells. Significant genes 
are listed (p < 0.002). 
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2.6 Locus Control Regions 
 Locus Control Regions are defined as genetic regulatory elements that control 
the expression of key genes involved in the specification of a cell fate. LCRs also 
confer tissue specificity and play an important role in the temporal upregulation of 
linked genes to physiologically relevant levels. In recent years, there has been a 
renewed focus on LCR biology as research into gene regulatory mechanisms made a 
giant leap in the era of genomics. The term, super-enhancers is now frequently used to 
describe LCRs and this rebranding in 2013 (Whyte et al., 2013) has been of some 
debate as there is yet to be a clear functional rationale to separate these modalities. 
However, trivial marketing ploys aside, the significance of such regulatory loci is 
becoming increasingly clear as more effort is poured into profiling the epigenetic 
landscape of various tissue types and cancer cells.  
 
 For clarity, it must be noted that there is a difference between an LCR and an 
enhancer. While functionally both enhancers and LCRs are gene regulatory loci, 
enhancers are known to exhibit a phenomenon known as ‘position effect.’ If a gene 
with an enhancer is introduced into the genome, the expression of that gene is not 
entirely dictated by the enhancer. Instead, the state of the chromatin in the region 
(accessibility) predicts the level of expression instead. While the enhancer is still 
critical for expression, it only influences the gene when permitted to do so by the 
preexisting nature of proximal chromatin. If the enhancer is coupled to a selectable 
marker, followed by the selection pressure then the cells that emerge are the ones 
where the insertion of the gene-enhancer locus was in a favorable region. When an 
enhancer is inserted into a region without any selection—for example when a 
transgene is inserted into a fertilized egg via microinjection—then the position effects 
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become clear as random insertion of the gene into the cells will result in ‘patchy’ 
expression. This is also known as position effect variegation or PEV.  
  
 On the other hand, LCRs have the ability to override PEV. They function as 
independent actors and do not rely on the chromatin state. Instead, the dictate the 
accessibility of the chromosome on their own terms through binding of master 
transcription factors, chromatin modifiers and other factors that can regulate these 
conditions. LCRs are also known to confer tissue specificity and the level of 
expression of linked genes is directly related to the copy number of the LCR. The 
DNA sequence of LCRs is obviously critical to their function and it has been shown 
that modification to LCRs (additions or deletions) have resulted in the emergence of 
PEV (Fraser & Grosveld, 1998). 
 
 The first LCR—also	referred	to	as	‘locus	activating	regions’	or	‘dominant	control	regions’	(Felsenfeld,	1992)—to be discovered and extensively studied is the 
cluster of five-DNase Hypersensitive regions around the b-globin	gene	(Grosveld,	van	Assendelft,	Greaves,	&	Kollias,	1987).	The	mechanisms	that	specifically	enact	LCR	function	are	still	not	fully	understood.	It	has	been	hypothesized	that	the	one	of	the	factors	that	influences	LCR	action	is	the	distance	of	the	genes	from	the	LCR	(Dillon,	Trimbom,	Strouboulis,	Fraser,	&	Grosveld,	1997).	Some	models	suggest	that	distal	genes	compete	with	proximal	ones	for	LCR	influence	in	a	random	contact	dependent	manner—more	proximal	genes	therefore	curry	more	favour	i.e.	are	upregulated	more	frequently	as	they	contact	the	LCR	more	frequently.				 While	these	early	studies	shed	light	onto	these	vital	regulatory	elements.	The	studies	over	the	last	5	years	have	expanded	that	knowledge	many	fold.	With	
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the	availability	of	ChIP-seq	data	for	various	transcription	factors,	histone	modifications,	chromatin	modulators	etc.,	groups	across	the	world	are	identifying	many	more	super	enhancers	that	regulate	differentiation	of	various	tissues.	Of	note	have	been	the	LCR’s/Super-enhancers	identified	in	embryonic	stem	cells	that	are	bound	by	the	master	transcription	factors	Oct4,	Sox2,	Nanog,	Klf4	and	Essrb	(Whyte	et	al.,	2013).	It	has	also	been	shown	that	differential	patterns	of	transcription	factor	binding	in	LCRs	is	related	to	the	signalling	pathways	involved	in	the	subsequent	cell	fate	decisions.	In	many	cases	a	master	transcription	factor,	downstream	of	a	signalling	cascade,	would	bind	an	LCR	proximal	to	a	gene	known	to	play	a	role	in	the	response	to	that	very	specific	signalling	cascade	(Chen	et	al.,	2008;	Mullen	et	al.,	2011).			 Another	hallmark	of	LCRs/super-enhancers	is	the	unusually	high	level	of	Mediator	binding.	Additionally,	RNA	PolII,	cofactors	and	chromatin	regulators	like	p300,	CBP	and	BRD4	have	been	shown	to	bind	these	loci	as	well.	The	mediator	complex	has	been	of	particular	interest	as	it	is	responsible	for	stabilizing	and	facilitating	long	range	enhancer	looping	interactions	and	the	extremely	high	concentration	of	mediator	subunits	(identified	via	ChIP-seq)	in	LCRs	speaks	to	their	functional	capability	of	bringing	many	loci	in	close	proximity	for	co-regulation.	A	simplified	depiction	of	the	manner	in	which	an	LCR	functions	is	shown	in	figure	2.15	(Maston,	Landt,	Snyder,	&	Green,	2012).			 There	are	many	known	surrogate	markers	to	establish	the	presence	of	an	LCR.	These	include	DNase	hypersensitive	sites,	H3K27Ac,	H3K4me2,	presence	of	histone	acetyltransferase	p300	or	H3K4me1	marks	(Creyghton	et	al.,	2010;	Heintzman	et	al.,	2009;	Yue	et	al.,	2014).	Of	these	marks	the	best	predictor	thus	
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far	has	been	the	histone	H3K27Ac	modification	and	will	be	used	as	the	main	surrogate	for	LCR	identity	in	this	body	of	work	as	well.	
Figure	2.15	Schematic	depicting	a	simplified	view	of	a	Locus	Control	Region	bound	by	multiple	transcription	factors	(TF),	mediator,	p300	and	RNA	polymerase	II.	Figure	from	Maston et al. Annual Review of Genomics and Human 
Genetics (Vol. 13)		 	
2.7	Hypothesis	From	the	perspective	of	Germinal	Center	B-cells,	the	data	shown	in	section	2.6.	indicates	that	the	enhancer	clusters	upstream	of	BCL6	in	human	GCBs	are	most	likely	functioning	collectively	as	an	LCR.	However,	a	set	of	criteria	ought	to	be	met	to	define	them	as	such.	To	that	extent,	we	decided	to	test	the	role	this	putative	LCR	might	be	playing	in	germinal	center	B-cells	by	deleting	them	in	a	mouse	model.	Based	on	our	hypothesis,	the	constitutive	deletion	of	a	syntenic,	functionally	conserved	LCR	in	mice	should	have	a	deleterious	effect	on	GC	
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formation.	However,	such	a	phenotype	should	be	specific	to	GC	B-cells	and	a	regulatory	relationship	between	the	genes	contacted	by	the	LCR	ought	to	be	established.	Therefore,	we	predicted	that	GC	formation	upon	immunization	in	a	would	be	reduced	in	a	knockout	mouse	model,	and	the	homologous	genes	in	mice	that	are	contacted	by	the	LCR	in	humans	should	also	show	lower	expression	levels.				 The	first	step	in	this	process	is	to	come	up	with	a	strategy	to	identify	and	then	delete	the	LCR	in	mice.	The	details	of	the	strategy	we	devised	are	described	in	Chapter	3. 
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Chapter 3-Generation of the LCR KO Mice 
 
3.1 Introduction 
 With an expanding trove of information about the state of enhancer clusters in 
human GCBs and DLBCL derived cell lines, we became curious about their role in 
GC physiology. Specifically, we hypothesized that the set of enhancers upstream of 
Bcl6 making extensive physical interactions with the Bcl6 promoter and other gene 
loci (on chromosome 3 in human GCBs compared to NBs) collectively qualify them as 
a putative Locus Control Region. By definition this implies that this putative LCR is 
involved in the regulation of Bcl6 expression and other genes vital for the formation of 
GCBs. We predicted that this LCR should be functionally conserved between human 
and murine GCBs i.e. while DNA sequence similarities may not be pronounced in a 
way that would permit straight forward elucidation of conserved regulatory 
mechanisms, the syntenic region should have open chromatin and enrichment of 
H3K27Ac marks in GCBs when compared to NBs. To assess the role of the LCR in 
GC formation, we decided to generate a knockout mouse model of the LCR. 
Coincidentally, the details of this endeavour were being discussed right around the 
time when the seminal papers on CRISPR-Cas9 system for genome editing had been 
published. 
 
 CRISPR, which refers to clustered regularly interspaced palindromic repeats, 
were first identified (though not named as such) by Japanese researchers in 1987 as 
short direct repeats in Escherichia coli (Ishino et al.). Over the next two decades, 
bioinformaticians and microbiologists determined that these sequences represent a the 
basis of an adaptive immune system in bacteria and the sequences themselves act as 
encoded memory of previous viral infections (Makarova et al.; Horvath and 
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Barrangou). In the mid 2000’s, new information about CRISPR associated (Cas) genes 
encoding proteins that possessed DNA modifying—nuclease and helicase motifs 
(Pourcel et al.; Jansen et al.; Haft et al.). The advances in the field starting coming in 
fast and type II CRISPR-Cas was shown to cut targeted DNA (Garneau et al.), and in 
2012 it was shown that Cas9 is an RNA directed endonuclease (Jinek, Chylinski, et 
al.). Within 6 months, a series of three papers showed that CRISPR-Cas9 can be 
utilized to edit DNA in human cells (Cong et al.; Jinek, East, et al.; Mali et al.). What 
has followed has been an incredible explosion of studies utilizing this system with far 
reaching possibilities for the future of biomedical research and gene therapies for 
personalized medicine. 
  
Soon thereafter, The Zhang lab published a CRISPR method that could be 
utilized to alter multiple genes via sgRNA in ‘one shot’ (Wang et al.). We utilized the 
published method to target the LCR in mice after identifying a ~166 Kb locus syntenic 
to the previously described LCR in humans.  
 
By definition, Locus Control Regions enhance the expression of linked genes 
in a tissue-specific fashion. The linked genes can be on the same or separate 
chromosomes, and it is hypothesized that the increased expression of these genes 
correlates with a the requirements of said tissue for development or differentiation 
purposes (Fraser and Grosveld; Li et al.). The putative murine BCL6 LCR—
chr16:24,119,037-24,285,604 mm10—is about 130 Kb upstream of the Bcl6 
transcription start site and is enriched for H3K27Ac marks (Figure 3.1) in GC derived 
B-cells (these cells are from tumors in the spleens from vavP-BCL2 mice which are 
GCB like cells. H3K27Ac called peaks from MINT ChIP in WT murine NB and GCB 
are shown in the UCSC browser tracks (Figure 3.2). 
	67	
 
 Figure 3.1 Tracks for H3K27Ac read densities (top) normalized to input for murine 
tissues including GC-derived malignant B-cells and other BCL6-expressing tissues. 
The region shaded in green represents the syntenic LCR targeted for CRISPR 
mediated deletion.  
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Figure 3.1 also shows tracks for H3K27Ac reads in various other murine 
tissues available through ENCODE (Yue et al.). These tissues include whole spleen, 
thymus, bone marrow, embryonic day 14.5 liver, adult heart, embryonic day 14.5 
heart, cerebellum, cortex and whole brain. The region shaded in green denotes the 
LCR, and from the H3K27ac read densities, it was postulated that the LCR must be 
specifically involved in regulating the expression of genes in GCB as it is the cell type 
with the most enrichment. While there is some enrichment of the acetylation mark in 
other tissues—in the thymus, bone marrow and cerebellum—it is not as wide spread 
and the enrichment is not comparable to GCB.  
 
 Figure 3.2 shows H3K27Ac peaks along with read densities from ATAC-seq 
(Assay for Transposase-Accessible Chromatin using sequencing) in WT murine NB 
and GCB. ATAC-seq is a relatively recent technique that can reveal regions of open 
chromatin and can be used to reliably evaluate nucleosome repositioning at loci 
between stages of differentiation. A benefit of using this technique over other 
modalities like DNase hypersensitivity is that ATAC allows a view into chromatin 
accessibility with relatively few cells whereas other techniques require millions of 
cells for adequate processing material. When comparing murine NB (blue track) to 
GCB (black track), it becomes obvious that there is a profound increase in chromatin 
accessibility in GCBs which can be further studied to evaluate transcription factor and 
chromatin modifier binding sites.  
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A quick glance at ATAC tracks leads to a reasonable argument that specific 
transcription factor binding sites should be targeted via CRISPR to study their effect 
on gene regulation from within the LCR. While this is sound reasoning, we chose to 
target the entire enhancer cluster (LCR) as a preliminary step to determine if there was 
a physiological role for the region. If the deletion leads to a phenotype it would be a 
reasonable second step to proceed in that direction. 
 
Figure 3.3 Bcl6 gene expression values in B-cell, T-Cell, Macrophage and Monocytes 
obtained through RNA-seq of sorted murine cells. Data from the Immunological 
Genome Project. Expression values are normalized by DESeq2. 
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As we hypothesized that the role of the LCR in primarily regulating BCL6 
expression it is of pertinence to assess expression in other cells/tissues known to 
require BCL6. These include T-follicular helper cells, cortical neurons, monocytes, 
and other B-cells in early stages of differentiation (pro B-cells) (Tiberi et al.; Dent et 
al.). Publically available RNA-seq from the Immunological Genome Project shows 
some of the cell types of interest within immune compartments (Figure 3.3)  (Heng 
and Painter). 
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3.2 Results 
 The schematic in figure 3.4 provides the stepwise workflow for the generation 
of the LCR KO mice once the sgRNAs required to target the LCR had been 
transcribed in-vivo. The guides were picked by utilizing the ‘guide RNA design tool’ 
available at crispr.mit.edu (Hsu et al.). Oligos encoding the sgRNA sequence are  
Figure 3.4 Schematic showing the steps involved in the generation of the LCR KO 
mouse.  
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annealed and then cloned into the pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid 
(Cong et al.) with the sgRNA backbone. The cloned plasmid was then used for a PCR 
amplification to introduce the T7 promoter at the 5’ end of and sgRNA constructs. The 
PCR amplified product was subsequently used as template DNA for in-vitro 
transcription with the Ambion MEGAshortscript T7 transcription kit. Initial IVT 
attempts yielded extremely low RNA concentrations which was eventually attributed 
to low level of RNase contamination. When the IVT was performed with ‘RNase-out’, 
the RNA concentration was enough for embryonic microinjections. The 
concentrations obtained for each attempt are listed in table 3.1. RNA concentration 
was measured with the qubit. 
 
Table 3.1 IVT sgRNA concentrations 
Attempt # mCr_BCL6enh_Tg1_1 mCr_BCL6enh_Tg3_2 Elution volume (ul) 
Without RNase-out. 
1 20 ng/ul 18 ng/ul 25 
2 26.8 ng/ul 19.1 ng/ul 25 
3 23 ng/ul 1o ng/ul 20 
With RNase-out. 
4 253 ng/ul 184 ng/ul 25 
 
The RNA was shipped on dry-ice to the Stem Cell and Transgenics Core at Cornell 
University, Ithaca, NY. At the core, the two sgRNAs were combined with Cas9 
mRNA and microinjected into mouse zygotes obtained from crosses between FVB/2J 
and C57BL/6 mice (of 10 donor mice, 6 had vaginal plugs within 24 hours when the 
zygotes were harvested). 117, one cell embryos were injected of which 81 reached the 
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two-cell stage. These 81 were eventually transplanted into four pseudo-pregnant mice. 
20 days post implantation, 15 pups were born between the four pregnant mice. Clipped 
toe tissue from 7-day old pups were shipped back for genotyping.  
 
Figure 3.5 Schematic of the putative BCL6 LCR in mice before and after CRISPR 
mediated deletion. Dotted lines show approximate distances between gene loci. The 
blue and green arrows represent primer pair used to genotype the founder mice. 
  
The genotyping strategy employed for the mice is described in the schematic in 
figure 3.5. A deletion of the LCR would result in a PCR product of 70bp (For_Tg1_1 
+ Rev_Tg3_2 primer pairs) as shown in the gel image (Figure 3.6). An intact LCR 
acts as a template for a 172bp PCR product (For_LCR1_1 + Rev_LCR1_1). On 
genotyping the 15 tails, we discovered that four of the pups had the deletion product 
and therefore would be candidates for further breeding. To confirm the deletion, we 
gel purified the deletion product and cloned it into a TOPO vector and sanger 
sequenced the product. Indeed, the product was not only the expected size but the 
sequence analysis matched that of the flanking loci at the 5’ and 3’ of the sgRNA 
binding sites (Figure 3.7) 
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Figure 3.6 Agarose gel with PCR product bands for the two genotyping primer pairs: 
Primer pair for For_Tg1_1 + Rev_Tg3_2 à 70bp product if LCR is deleted. 
For_LCR1_1 + Rev_LCR1_1 à 172bp product even if one copy of the LCR is 
present in the genome. 
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Figure 3.7 Sequencing results from repair junction in LCR KO mouse. 
 
The blue arrows in figure 3.7 denote the loci where the PCR primers bind 
whereas the red vertical arrow points at the junction where the post deletion repair 
occurred. While indel formations are frequently reported when non-homologous-end-
joining mechanisms repair DNA breaks post CRISPR-Cas9 mediated deletion. 
However, in the mice, remarkably, there was no indels formed. This observation led to 
some skepticism. While the sequencing results were definitive, I decided to perform 
another test to confirm if the deletion of the LCR was complete and proper. This was 
achieved through a TaqMan Assay which is a qPCR based genotyping method. 
Taqman probes were ordered and the loci tey bound are depicted in figure 3.8. 
Figure 3.8 Loci where the 4 different TaqMan probes bind in the mouse genome. 
Probe#1 and Probe#3 bind within the LCR. Probe#2 binds outside the LCR proximal 
to Lpp. Probe#4 binds within the gene body of Bcl6. 
 
 The assay results are shown in figure 3.9, and they confirmed an interesting 
and predictable outcome. While the deletion was true, it was chimeric, i.e. not every 
cell in the mouse had the deletion. The purported reason for this is that the deletion 
process mediated via CRISPR does not occur at the one cell stage (zygote). Instead, as 
the cells grow ex-vivo into a blastocyst pre-impantation. Some of the cells may escape 
the deletion due to a number of reasons including insufficient distribution of the Cas9 
chr16: 24,000,000 24,050,000 24,100,000 24,150,000 24,200,000 24,250,000 24,300,000 24,350,000 24,400,000
sgRNA target coordinates for Cas9 mediated deletion
RefSeq Genes
Taqman probes
Tg1_1 Tg3_2
Bcl6 Lpp
Probe4 Probe3
Probe1
Probe2
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mRNA or the sgRNA itself. When the embryos with the deletion continue to develop 
the distribution of the deletion becomes patchy and leads to a chimera. This is 
reflected in figure 3.9 as the copy number for the LCR is a non-integer. This meant 
that for a constitutive homozygous deletion of the LCR in the mouse, we would have 
to back cross the pups to WT C57BL/6 and monitor litter genotypes to select the pups 
with first, a heterozygous deletion and subsequently after crossing the heterozygous 
mice, monitor for homozygous deletions. This is exactly the strategy we employed to 
obtain mice for phenotyping purposes.  
 
 Another notable observation is that not all four pups seemed to have the 
deletion. Only three of the four were chimeras whereas ‘founder pup #7’ had no copy-
number alteration compared to the WT control mouse. The appearance of a deletion 
product in the PCR performed for founder pup #7 was most likely due to 
contamination. This further highlighted the importance of employing orthogonal 
techniques to confirm deletions when utilizing CRISPR-Cas9 for genome editing. The 
three founders were maintained as separate LCR KO lines in the animal facility. This 
proved to be an important step as each line could be treated as an independent 
biological control and any observed phenotype would be considered valid if all three 
lines exhibited the same defect. The backcrossing of the mice to WT C57BL/6 was 
important to obtain constitutive heterozygous mice that could be used for further 
breeding but it also proved important to dilute out any off-target effects that might 
have resulted from non-specific binding of the sgRNA. Every successive generation 
bred with a WT mouse would theoretically remove 50% of the off-target effects and 
therefore mice separated by 6 generations from the founder can be assumed to exhibit 
phenotypes that are attributable to the deletion and no other genomic lesion. 
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Figure 3.9 Analysis of the TaqMan Copy number qPCR performed on the founder 
mice using the Applied Biosystems CopyCallerâ software v2.0. Error bars represent 
technical replicates. Pink is Probe#1 (for LCR), Blue is Probe#3 (for LCR) and Green 
is Probe#4 (for Bcl6). The analysis shows that founder#7 was most likely WT. The 
other three founders (#2, #3 and #9) were chimeras for the LCR deletion. The third bar 
from the left for founder pup #2 is highlighted and is therefore labeled dark blue.  
 
 While the mice were eventually utilized to assess GC formation post SRBC 
immunization, the original mouse line for the founders created a problem that needed 
to be addressed for the purpose of mixed bone marrow chimera experiments. Usually, 
such experiments utilize two variants of CD45—CD45.1 and CD45.2. However, the 
embryos utilized for the microinjection of sgRNAs and Cas9 mRNA were from 
FVB/NJ and B6(Cg)-Tyrc-26/J mice. The crossing of these two mice provides zygotes 
which are larger than C57BL/6 zygotes and makes microinjections easier. However, 
the cross also results in the mixing of the two CD45 variants. This limited our ability 
to use these markers to differentiate mixed bone marrows. However, once we became 
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of this problem we utilized GFP expressing mice for those experiments. The 
phenotyping of the mice and the subsequent experiments based on the new 
observations are described in detail in chapter 4. 
 
3.3 Materials and Methods 
 
3.3.1 Generation of LCR KO mouse via CRISPR 
3.3.1-1 Designing and Cloning guides into pX330-U6-Chimeric_BB-CBh-hSpCas9 
plasmid 
Guide RNA sequences targeting the regions flanking the 166Kb LCR in mice were 
selected with the CRISPR design tool at http://crispr.mit.edu/. Complementary oligos 
were ordered from integrated DNA technologies, annealed and cloned into the BbsI 
restriction enzyme digestion site of the pX330-U6-Chimeric_BB-CBh-hSpCas9 
plasmid. The steps are described in further detail below. 
 
Annealing oligos  
 2 µL oligo 1 (100µM) , 2 µL oligo 2 (100µM) , 4 µL 5X T4 Ligation Buffer 
(NEB), and 12 µL ddH2O are added per tube. The tubes are incubated at 95 degree C 
for 3 minutes and subsequently cooled down at room temperature for 1 hour.  
 
BbsI digestion of pX330 
 2µL (1 µg) of pX330, 1 µL of NEB BbsI enzyme, 5 µL of 10X NE buffer 2.1, 
and 42 µL of ddH2O for a total of 50µL per reaction. Plasmid is digested at 37 degree 
C for 30 minutes. The digested plasmid is gel purified using the QIAquick gel 
extraction kit. 
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Ligation 
 50 ng of digested pX330, 1 µL of annealed oligo duplex (diluted 1:250), 5µL 
of 2X Quick ligation Buffer (NEB), and x µL of ddH2O are added (x is the volume to 
bring the reaction to 10 µL. Then add 1 µL of Quick Ligase for a final total volume of 
11ul. Ligation is performed at room temperature for 15 minutes. 
 
Transformation 
 Competent DH5-a cells are used for transformation with the ligated pX330 
plasmids. 150ul of 0.1M Calcium Chloride (sterile conditions, use flame) is added to a 
tube of DH5-a cells. The competent cells are split into four 1.5 ml eppendorf tubes 
kept on ice. 2.5µl of ligation reaction (~12.5ng of DNA) is added to 50ul of competent 
cells. Tubes are gently flicked and incubated on ice for 30 minutes. The cells are then 
heat shocked at 42 degree C for 30 seconds. Tubes are placed back on ice for 10 
minutes. Transfer the competent cells to 250ul of S.O.C. media (without antibiotics). 
Incubate with shaking at 37 degree C for 1 hour. After incubation plate the cells on a 
carbenicillin plate, and incubate overnight at 37 degree C. 
PCR amplification (and addition of T7 promoter) 
 The two primers ordered for each amplification are as follows: 
Primer 1 (T7-target R#_For): This is specific to our sgRNA but has the T7 promoter 
sequence (TTAATACGACTCACTATAG) at the 5’ end followed by the CACC (for 
the BbsI site) followed the by the sequence for the guide RNA target (GN20). The 
sequences of these oligos are listed in table 3.2 
Primer 2: A universal primer (T7-sgR Rev) specific for the pX330 plasmid: 
AAAAGCACCGACTCGGTGCC.   
Setup multiple PCR reactions (~5) for sufficient amount of amplified product. 
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PCR conditions: 
Component Per reaction Volume for 5 reactions (X 6) 
Water 22.6 µL 135.6 µL 
~20ng plasmid DNA 1 µL 6 µL 
10X buffer 3 µL 18 µL 
25mM dNTP 0.3 µL 1.8 µL 
Primer 1 (10 µM) 1.5 µL 9 µL 
Primer 2 (10 µM) 1.5 µL 9 µL 
Taq polymerase 0.1 µL 0.6 µL 
Total Volume 30 µL 180 µL 
 
Thermocycler setup: 
Step 1-1 Cycle at 95 degree C for 1 minute. 
Step 2-30 cycles of [95 degree C for 30 seconds, (Primer Tm-5 degree C) for 30 
seconds, 72 degree C for 1 minute] 
Step 3-1 Cycle at 72 degree C for 10 minutes. 
Qiagen PCR cleanup kit is used to purify the amplified product. 
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Table 3.2 Single guide RNA sequences, and primer sequences used for cloning into 
the pX330 plasmid.  
Name Sequence (5’ to 3’) Purpose 
mCr_BCL6enh_Tg1_1F CACCGATTTTTGTGAGTACGGATT 
CRISPR oligo for 
cloning in pX330 
mCr_BCL6enh_Tg1_1R AAACAATCCGTACTCACAAAAATC 
CRISPR oligo for 
cloning in pX330 
mCr_BCL6enh_Tg3_2F CACCGTGTCAGCGACTCATAAGTTA 
CRISPR oligo for 
cloning in pX330 
mCr_BCL6enh_Tg3_2R AAACTAACTTATGAGTCGCTGACAC 
CRISPR oligo for 
cloning in pX330 
TgSpBCL6enh_Tg1_1 
TTAATACGACTCACTATAGCACCGATTTTT
GTGAGTACGGATT 
Forward primer for 
amplification of 
template for IVT 
of left sgRNA 
TgSpBCL6enh_Tg3_2 
TTAATACGACTCACTATAGCACCGTGTCA
GCGACTCATAAGTTA 
Forward primer for 
amplification of 
template for IVT 
of left sgRNA 
T7-sgR_Rev AAAAGCACCGACTCGGTGCC 
Reverse primer for 
amplification of 
template for IVT 
of both sgRNA 
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3.3.1-2 In Vitro transcription and purification of short guiding chimeric RNA 
 The kit used for IVT is the Ambion MEGAshortscript T7 Transcription kit 
(Life Technologies). The T7 10X Reaction Buffer, the four ribonucleotide solutions, 
and Water are thawed at room temperature. Briefly vortex the T7 10X Reaction Buffer 
and ribonucleotide solutions. Microfuge all reagents briefly before opening to prevent 
loss and/or contamination of material that may be present around the rim of the tube. 
Keep the T7 Enzyme Mix on ice during assembly of the reaction. 
  Use an RNase-free microfuge tube at room temperature in the order below. For 
convenience, all four nucleotides are premixed; added 8 µL of the mixture to a 
standard 20 µL reaction instead of adding the ribonucleotides separately. 
 
 
Component Amount 
Water (Nuclease Free) To bring final volume to 20 µL 
T7 UTP solution 2 µL 
T7 ATP solution 2 µL 
T7 CTP solution 2 µL 
T7 GTP solution 2 µL 
T7 10X reaction Buffer 2 µL 
Template DNA 1 µg in less than or equal to 8 µL 
T7 Enzyme mix 2 µL 
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 The volumes above are for a single 20 µL reaction. Reactions maybe scaled as 
needed. Components in the transcription buffer can lead to precipitation of the 
template DNA if the reaction is assembled on ice. 
 The reaction contents are mixed thoroughly by gently flicking the tube, and 
then microfuged briefly to collect the reaction mixture at the bottom of the tube. 
Samples are incubated at 37°C for 4 hours. Once IVT is complete, added1 µL of 
TURBO DNase and incubate at 37°C for 15 min 
 
Termination of the Reaction and RNA Recovery 
 The degree of purification required after the transcription reaction depends on 
the downstream application of the transcribed RNA. We used the Ambion MEGAclear 
kit (Life Technologies) for purity compatible with zygotic injections. 
 
 The MEGAclear™ Kit (Ambion P/N AM1908) is a glass filter-based system 
for purification RNA transcripts (>100 nt) from salts, free nucleotides, and enzymes in 
an easy 15-minute procedure that requires no organic solvents. The steps involved in 
purification were as follows: We brought the RNA sample to 100 µL with elution 
solution. Mixed gently but thoroughly. Added 350 µL of binding solution concentrate 
to the sample. Mixed gently by pipetting. Then added 250 µL of 100% ethanol to the 
sample. Mixed gently with pipette. Applied the sample to the filter. The filter cartridge 
is inserted into one of the collection and elution tubes supplied. Pipetted the RNA 
mixture onto the filter cartridge. Centrifuged for ~15 seconds to 1 min, or until the 
mixture has passed through the filter at 10,000–15,000 × g. The flow through is 
discarded, and the collection and elution tube is reused for the washing steps. Washed 
with 2 × 500 µL wash solution (with added ethanol) and centrifuging again at 10,000g 
for 30 seconds each time. Centrifuge one last time after discarding the wash solution 
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after the second wash. Elute RNA as follows: First pre-heated 110 µL of elution 
solution per sample to 95° C. Apply 50 µL of the pre-heated elution solution to the 
center of the filter cartridge, close the cap of the tube and centrifuge for 1 min at room 
temperature (RCF 10,000–15,000 x g) to elute the RNA.   
3.3.1-3 Embryonic microinjections of sgRNA  
 The embryonic microinjection of the sgRNA pair flanking the LCR along with 
Cas9 mRNA was in F1 hybrid zygotes from FVB/NJ and B6(Cg)-Tyrc-26/J mice. The 
microinjections were performed as described by Singh et al (1) at the Cornell core 
facility in Ithaca, NY. 81 of the 117 one-cell embryos progressed to the two-cell stage 
and were transferred into 4 pseudo-pregnant mice (Figure 3.4). A total of 15 pups 
were born from the resulting pregnancy. 
 
3.3.2 Genotyping mice 
 Genomic DNA was isolated from the 15 pups (and all subsequent pups from 
breeding LCR +/- and -/- mice) using the method described here. Proteinase K 
(10mg/ml) is added to the reagent (Viagen directPCR (tail) lysis reagent Cat#102-T) 
to a final conc. Of 0.5 mg/ml. Added 275ul of reagent (with 0.5mg/ml of Proteinase 
K) to each tube with tail tissue. Placed tube on thermo-mixer set at 700rpm and 55 
degree C. Incubate tubes 4-16 hours. Next day, raise the temperature of the thermo-
mixer to 95 degree C and incubate the tubes for an additional 45 minutes with shaking 
at 300rpm. Centrifuge tubes at 5000 rpm for 3 minutes. Transfer 200 µl of the 
supernatant (hair and other debris will be in the pellet) to new 1.5 ml eppendorf tubes 
Add 12.5 µl of 4M NaCl to bring the final concentration of the sample to 250 mM 
NaCl. Then add 0.7 volumes of Isopropanol to each tube and centrifuge the sample on 
bench-top centrifuge for 1 hour at 16000g (16 degree C). Carefully remove 
supernatant. Wash the DNA pellet by adding 1 ml of 70% ethanol to each tube and 
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then centrifuging for 30 minutes at 16000g. Again, carefully remove the supernatant. 
Allow the samples air-dry for 5 minutes and then add 50uL of nuclease free water to 
each sample. Gently tap the tubes to mix the sample and measure the DNA 
concentration on a nanodrop. 
 
Deletion of the LCR was confirmed by the presence of a PCR product from a 
primer pair that flanked the LCR (Forward primer: For_Tg1_1_q: 
CATCCGTCTTCCTGAACCAT; Reverse primer: Rev_Tg3_2_q: 
GCACGTGCTTTCCCTACTTT) (Figure 3.5). Additionally, the deletion of LCR was 
confirmed with a primer pair complementary to a region within the deleted LCR 
(Forward primer: For_LCR1_1_q: GCTTGTGGACTTGCATCTCA; Reverse primer: 
Rev_LCR1_1_q: TGTGGGTCTGTGTGTGAACAT). PCR with these primers 
revealed 3 of the 15 pups to have a deletion (Figure 3.6).  
 
 The LCR deletion was further confirmed with a TaqMan copy number assay 
using probes for the deleted region (Assay ID: Mm00451576_Cn, Chr16: 24159427-
Probe#3 and Assay ID: Mm00451574_Cn, Chr16:24168442-Probe#1). Another probe 
(Probe#4) specific for the BCL6 locus (Assay ID: Mm00445402_Cn, Chr16: 
23978604) was used as a control. Copy number assay results revealed the founders to 
be chimeras for the deletion instead of pure knockouts. (Figure 3.8 and 3.9). 
 
 The founder mice were crossed with wildtype C57BL/6 mice. PCR products 
from the resulting pups along with that from the founder mice were cloned into the pcr 
Blunt-II TOPO vector and sequenced using the M13R primer 
(CAGGAAACAGCTATGAC) by Genewiz DNA sequencing services. The 
sequencing confirmed the presence of the deletion (Figure 3.7). 
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Chapter 4-Phenotypic Characterization of the LCR KO mice 
 
4.1 Introduction 
Previous studies on Bcl6-/- mice have revealed a number of pathologies in mice 
(Dent et al.). In these mice, SRBC immunization—which is a gold standard method to 
assess T-cell dependent immune responses (Luster, Munson, et al.; Luster, Portier, et 
al.)—results in a complete loss of GC formation. Spleen sections also reveal 
eosinophilic infiltrations, the reason for which is not entirely clear. Hematoxylin and 
Eosin (H&E) staining of lung and heart reveals widespread inflammation (pulmonary 
vasculitis) and myocarditis. The knockout mice also have cellular infiltrates in these 
tissues which are composed of mononuclear cells and eosinophils. At approximately 
3-weeks after birth, the Bcl6-/- mice start showing growth retardation compared to WT 
mice. Other studies have also revealed a critical role for BCL6 in neurogenesis (Tiberi 
et al.; Leamey et al.), and cortical neurons have been shown to express BCL6 at high 
levels in mice.  
 
Since we hypothesized the LCR to be regulating BCL6 expression, we used the 
phenotype of BCL6-/- mice to guide our initial assessment of the LCR KO mice. 
Additionally, as the deletion is germline, it warranted analysis of all tissues where 
BCL6 might play a role.   
 
After establishing three separate founder mice for the LCR deletion, we 
maintained the mice bred from each founder as separate colonies. This set up provided 
an opportunity to replicate the results of our analysis in a truly independent fashion. 
After back crossing the chimeric founders with WT C57BL/6 mice, we obtained mice 
with a single copy of the LCR (LCR hets), which were subsequently crossed to obtain 
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the LCR-/- mice. We obtained these mice at expected mendelian rations and no 
significant male:female bias was observed in any of the breedings in the three 
colonies. For controls, we used the WT littermates of the LCR-/- animals.  
 
4.2 Results 
 
4.2.1 LCR KO (-/-) mice have a specific and complete GC formation defect 
 
For the pilot experiment, we used mice from founder #9. We immunized 10-
11-week-old mice with SRBC (via intraperitoneal injections) and sacrificed them 10 
days later to collect the spleens. We used 5 WT and 4 LCR-/- mice for this experiment. 
The processed splenocytes were stained with fluorophore conjugated antibodies to 
assess GCB, NB, centroblasts and centrocytes. The mice (pre-euthanasia) and the 
spleens (post-euthanasia) were also weighed. Flow cytometry revealed an almost 
complete loss of GCBs (B220+, FAS+, CD38-, DAPI-) in LCR deficient mice 
compared to WT mice (P value = 0.002, two tailed unpaired t-test) (Figure 4.1b). 
There were no statistically significant differences between WT and LCR KO when 
assessing total B-cell (B220+, DAPI-), marginal zone B-cell (B220+, CD21hi, CD23lo 
DAPI-), or follicular B-cell (B220+, CD21lo, CD23hi DAPI-) proportions (Figure 
4.1a & c). Furthermore, there were no differences observed in overall mouse or spleen 
weights between the two groups (Figure 4.1d). This exciting result confirmed our 
hypothesis that the LCR was critical for GC physiology. However, the pilot 
experiment did not assess a number of other cellular compartments that might be of 
interest from an immunological perspective. To address those questions, we repeated 
the experiment with another founder colony (founder#3). 
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Figure 4.1 (A-C) Representative flow-cytometry plots along with bar plots 
quantifying splenic B-cells, splenic GCB and Follicular and Marginal Zone B-cells.  
(D) Bar plots representing the weights of the mice and the spleen.  
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 The experiment was repeated with 5 LCR KO and 4 WT littermate control 
mice. The experiment was setup in the exact same manner as the pilot, with the 
animals being sacrificed 10 days post immunization with SRBC. All of the 
observations reported from the pilot experiment were successfully replicated. Flow 
cytometry again revealed the complete loss of GCBs (B220+, Fas+, CD38-, and 
DAPI-) in LCR deficient mice compared to WT mice (P value= 0.0254, two tailed 
unpaired t-test) (Figure 4.2b & f). We also stained the splenocytes with another 
antibody mix for GCBs (B220+, Fas+, GL7+ and DAPI-) and reached the same 
conclusion (P value = 0.0056, two tailed unpaired t-test) (Figure 4.3a & d). As 
observed earlier, there were no statistically significant differences between WT and 
LCR KO when assessing total B-cell (B220+, DAPI-), marginal zone B-cell (B220+, 
CD21hi, CD23lo DAPI-), or follicular B-cell (B220+, CD21lo, CD23hi DAPI-) 
proportions (Figure 4.2a, c, e, g & h). There were no differences observed in the 
overall mouse or spleen weights between the two groups (Figure 4.2d).  
 
 The additional stains for flow cytometry in the second experiment include 
those for T-cells and Monocytes. As was originally hypothesized, the LCR defect 
should be specific to GCBs, and in line with this idea, there were no differences 
observed in overall NB, Monocyte (Figure 4.3b, c, e & f) or T-cell proportions (n.d., 
two tailed unpaired t-test) (Figure 4.4). 
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Figure 4.2 (A-C) Representative flow-cytometry plots for splenic B-cells, splenic 
GCBs and Follicular and Marginal Zone B-cells.  (D) Bar plots representing the 
weights of the mice and the spleen. (E-H) Bar plots quantifying the splenic B-cells, 
GCBs, Marginal Zone B-cells and Follicular B-cells.   
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Figure 4.3 (A-C) Representative flow-cytometry plots for splenic GCBs (B220+, 
Fas+, GL7+ and DAPI-), Naïve B-cells and Monocytes. (D-F) Bar plots quantifying 
the splenic GCBs, Naive B-cells and Monocytes.   
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Figure 4.4 Representative flow-cytometry plot for total splenic T-cells along with bar 
plot quantifying the T-cells between the two groups. No significant difference is 
observed between LCR KO and WT mice.  
 
In addition to the analysis of cell populations in the spleen via flow cytometry, 
we also analysed tissue sections via immunohistochemistry. Spleen sections were 
stained using peanut agglutinin (a GCB marker), BCL6, B220, H&E, Ki-67 and CD3 
(Figure 4.6 & 4.7). Analysis of the PNA stained sections revealed the profound defect 
in the formation of GCs in the LCR deficient spleens compared to WT. We quantified 
the germinal centers in the PNA stained images and plotted the total area of GCs per 
unit area of the spleen, which reflected the differences seen in the flow cytometry data 
(P value = 0.0013, two-tailed, unpaired t test) (Figure 4.5). 
Figure 4.5 Bar plot representing the splenic area occupied by GCs based on PNA-IHC 
in WT versus LCR-deficient mice. 
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Figure 4.6 Immunohistochemistry images of WT and LCR KO mouse spleens stained 
for PNA, BCL6, and B220. 
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Figure 4.7 Immunohistochemistry images of WT and LCR KO mouse spleens stained 
with H&E, and for Ki67 and CD3. 
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Figure 4.8 Representative images of H&E-stained bone marrow, heart and lung 
sections from the WT and LCR-deficient mice. No differences observed between the 
two groups.  
 
 Unlike the phenotype of BCL6-/- mice, the LCR KO mice do not have any 
apparent inflammatory pathologies in lung or cardiac tissue (Figure 4.8). The analysis 
of the images was performed by Dr. Sebastien Monette from the WCMC and MSKCC 
lab of comparative pathology.   
 
	100	
Figure 4.9 Representative images of BCL6 stained brain sections from WT (left) and 
LCR-deficient (right) mice. Sc is the subiculum (a region inferior to the 
hippocampus). Top to bottom, sequentially zoomed in images of the subiculum with 
normal BCL6 staining in both WT and LCR KO mice. 
 
 An interesting and relevant observation was made when analysing the BCL6 
stained brain sections from the WT and LCR KO mice (Figure 4.9). While the 
assertion that the LCR regulates expression of Bcl6 may be true—though not 
definitively proven at this point—it is interesting to observe that another tissue that has 
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been known to require BCL6 for development and differentiation remains unaffected. 
As mentioned earlier, cortical neurons are known to require BCL6 for development 
during early stages of brain development in mice. The lack of the LCR in the mice is 
clearly a critical deficiency with regards to the humoral immune response, but has no 
apparent effect on the neurons. This observation further supports the idea that the 
region of the genome identified as the putative Bcl6 LCR is indeed an LCR as it seems 
to have a tissue specific phenotype. 
 
 We also performed a survival study for the LCR KO, LCR het and WT 
(littermate) mice. No significant differences were observed in the survival curves of 
the three groups (Figure 4.10). 
Figure 4.10 Kaplan-Meier plot for WT, LCR KO (-/-) and LCR het (+/-) mice. Log-
rank (Mantel-Cox ) tests reveals no significant differences between any of the survival 
curves. 
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4.2.2 The GC defect in LCR KO mice is GC intrinsic, and not related to TFH. 
 An unaddressed yet extremely important question with respect to the defect in 
GC formation in the LCR KO mice was whether the origin of the defect was GCBs or 
TFH. These specialized T-helper cells are touted to provide at least seven different 
types of ‘help’ to B-cells. These include survival, proliferation and hypermutation 
signals via BAFF, IL-4, IL-21 and CD40 ligand stimulation, adhesion and attraction 
ligands via SLAM associated proteins (SAP) and CXCL13, and immunoglobulin class 
switching, and plasma cell differentiation signals via IL-4, IL-17, TGFβ and IL-21 
(Crotty). Therefore, the origin of a defect in GC formation could potentially be a 
defect in the TFH compartment.  
 
 To determine if the GC defect is cell intrinsic, we decided to perform a mixed 
bone marrow chimera experiment. For this we would normally utilize the CD45.1-
CD45.2 system to differentiate between the lymphocytes originating from different 
mice. However, the LCR KO mice were both CD45.1 and CD45.2 positive. To 
overcome this problem, we decided to use GFP as a marker to differentiate the WT 
and LCR-KO cells. We purchased C57BL/6-Tg (CAG-EGFP)131Osb/LeySopJ (Stock 
no. 006567) mice from Jackson labs. A robust level of GFP expression is reported in 
both bone marrow and splenocytes of these mice, as shown in the Jackson labs data 
sheet  (Figure 4.11) (Okabe et al.). 
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Figure 4.11 Relative proportions of GFP expressing cells in the three different stocks 
of the C57BL/6-Tg (CAG-EGFP)131Osb/LeySopJ mice.  
 
 The GFP mice were deemed suitable to provide WT bone marrow. However, 
before performing the experiment we decided to test engraftment of the GFP bone 
marrow when mixed with regular WT bone marrow (from C57BL/6 mice not 
expressing GFP). The layout of the test is shown in figure 4.12. The results (Figure 
4.13) show that the splenic GCBs post-immunization approximate the GFP 
proportions in the transplanted mixed bone marrow. The mouse that received only 
GFP positive bone marrow has 89% of the GCBs in the GFP positive window. The 
mouse that received a 1:1 mix of GFP: non-GFP bone marrow has a 42:58 ratio in the 
GC compartment. This was deemed a promising result as minor deviations from the 
original ratio were to be expected. We therefore proceeded to determine the role of 
TFH in the LCR KO related GC defect by performing an experiment where the LCR 
KO bone marrow would be mixed with the WT GFP positive bone marrow.   
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Figure 4.12 Schematic of the mixed bone marrow transplant experiment performed to 
evaluate engraftment of GFP positive bone marrow with non-GFP bone marrow.   
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Figure 4.13 Representative flow plots showing relative proportions of GFP positive 
cells in the GC compartment post mixed BMT. 
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Figure 4.14 Schematic of the mixed bone marrow experiment to evaluate if the LCR 
KO mice have a GCB intrinsic defect or a TFH intrinsic defect. The groups on the right 
side of the figure depict the ratio and type of cells mixed together. 
 
We performed the transplant with 5 groups. Group 1: 50% GFP (WT) + 50% 
WT C57BL/6: 6 recipient mice; Group 2: 50% GFP (WT) + 50% LCR KO Homo: 6 
recipient mice; Group 3: 100% GFP mice: 4 recipient mice; Group 4: 100% WT 
C57BL/6 mice (non GFP): 3 recipient mice; and Group 5: 100% LCR KO mice: 3 
recipient mice (Figure 4.14). After the transplant, the mice were allowed 4 weeks for 
engraftment and subsequently immunized with SRBC to evaluate the cells of interest. 
The gating strategy for both GCB and TFH-cells are shown in figures 4.15 and 4.16.  
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Figure 4.15 Gating strategy for evaluation of relative proportions of GFP positive 
cells in stained splenic GCBs.  
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Figure 4.16 Gating strategy for evaluation of relative proportions of GFP positive 
cells in stained splenic TFH cells.  
 
 GC formation was evaluated 10 days post immunization and, as expected, 
groups 1-4 formed germinal centers (as evident from the GCB and TFH proportions 
observed through flow cytometry) (Figure 4.17). Group 5 (which only received LCR 
KO bone marrow) did not form any GCs. However, each group had comparable levels 
of B and T cells (Figure 4.17).  
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Figure 4.17 Plots representing total B-Cells (top left), total T-Cells (top right), GCB 
(bottom left) and TFH (bottom right) proportions in splenocytes from mice in the 
mixed bone marrow chimera experiment. 
 
Upon analysis of the relative proportion of GFP positive cells in each cell 
compartment, interesting observations were made (Figure 4.18). In group 1 (1:1 ratio 
of WT-GFP and WT-non-GFP bone marrow), both the GCB and TFH compartments 
had GFP and non-GFP cells. The higher proportion of non-GFP cells in both the total 
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T-cell and TFH compartments had been noted and interpreted to be a result of slightly 
lower level of GFP being expressed in the T-cells. The fact that the TFH compartment 
displayed the same bias as the total T-cell compartment assuaged our concerns as 
reasonable conclusions from the experiment could still be made.  
 
In group 2 (1:1 ration of WT-GFP and LCR KO bone marrow), the GFP 
proportions in GCB and TFH compartments had a story to tell (Figure 4.18). In the 
GCB compartment, 93.62 ± 0.6052% (mean ± SEM), of the cells were GFP positive 
and 6.387 ± 0.6081% (mean ± SEM) were non-GFP cells (n=6), indicating that only 
the WT-GFP cells had contributed to this cell population and the LCR deficient non-
GFP cells were incapable of forming GCBs. The difference in the mean was -87.23 ± 
0.8579% with a 95% confidence interval of -89.14 to -85.32. (two tailed t-test with 
welch’s correction). The TFH compartment on the other hand, had a more equitable 
distribution of GFP positive and negative cells. Here, the GFP positive cells were 
60.75 ± 7.163% (mean ± SEM) and the non-GFP LCR KO cells represented 39.25 ± 
7.163% (mean ± SEM) of the TFH cells. The difference between the means of GFP 
positive and negative in the TFH compartment was -21.50 ± 10.13%. This difference is 
statistically non-significant with a 95% confidence interval from -44.07 to 1.070 (two 
tailed t-test with welch’s correction). These results conclusively proved that the LCR 
deficient mice had a GC formation defect that was directly tied to a defect within the 
GCB and not TFH cells.  
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Figure 4.18 Relative proportions of GFP positive cells in groups that received mixed 
bone marrow transplants. Total B-Cells (top left), total T-Cells (top right), GCB 
(bottom left) and TFH (bottom right). Error bars are SEM. Statistics in text. 
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4.2.3 The LCR ought to be in cis with Bcl6 to allow GCB formation 
 While the LCR-/- mice display a severe GC defect, mice with one copy of the 
LCR consistenly form germinal centers, albeit to a lesser extent when compared to 
WT mice. At first glance, this observation led us to believe that there might be a dose 
response. This explanation is not completely without reason. One of the earliest 
observations pertaining to LCR biology includes the copy number dependent 
increased expression of genes linked in cis to LCRs (Grosveld et al.). However, in a 
number of experiments, the deviation from the mean would often be large, to the 
extent that differences between WT and heterozygous LCR KO mice became difficult 
to establish and explain. We hypothesized a relatively complex idea as an explanation 
for this observation (the hypothesis is contingent upon another unproven hypothesis 
that BCL6 expression is monoallelic). We proposed that the Bcl6 gene—which is 
undergoing transcription at low levels , as observed in NB-cells (Figure 3.3)—requires 
an early ‘boost’ from the LCR in cis during the NB to GCB transition. If the LCR is 
not in cis, then the level of expression required by the transitioning cells would not be 
sufficent for GCB formation.  
 
 To test a part of this hypothesis, we came up with a breeding strategy with 
Bcl6+/- mice and the LCR-/- mice that would result in Bcl6+/-LCR+/- (double het) mice. 
These mice (without any crossover between the two loci) would result in the loci 
being in single copies and in trans (Figure 4.19). According to our hypothesis, these 
mice should not be able to make any GCBs.     
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Figure 4.19 Schematic for breeding straegy employed to obtain BCL6+/-;LCR+/- mice.   
 
 A pilot experiment was performed with the following groups of mice. WT 
(n=3), LCR KO (n=3), double hets (n=6), BCL6 hets (n=3) and LCR hets (n=2). Mice 
were between 8-10 weeks at the time if SRBC immunization. The results show that the 
double heterozygous phenocopy the LCR KO mice—the ability to form GCBs is 
completely abrogated (Figure 4.20). Even with relatively smaller numbers of mice in 
the LCR het and Bcl6 het groups, the difference between the double hets and these two 
groups is staistically significant (compared to LCR hets P value  < 0.001, compared to 
BCL6 hets P value < 0.0001, two tailed t-test with welch’s correction). The gating 
strategy is depicted in figure 4.21. To validate these results we repeated the 
experiment with more mice in each group (Figure 4.22). 
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Figure 4.20 Plot quantifying live GCB (% of B220+, IgD-) in spleen from flow 
cytometry data. Error bars are SEM. Performed a two-tailed t-test with welch’s 
correction.  
Figure 4.21 Flow cytometry plots showing GC proportions from pilot experiment 
with double heterozygous Bcl6+/-; LCR+/- mice.  
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Figure 4.22 Plot quantifying live, total B-cells proportions in spleen (top) and GCB 
(bottom) % of live B220+ cells in spleen, from flow cytometry data. Error bars are 
SEM. Performed a two-tailed t-test with welch’s correction. *** means P value < 
0.001, **** means P value < 0.0001. 
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When the experiment was repeated, we had WT (n=10), LCR KO (n=11), 
double hets (n=8), BCL6 hets (n=8), LCR hets (n=11) and unimmunized WT (n=3) 
mice. Mice were between 8-10 weeks at the time of SRBC immunization. There were 
no significant differences between any of the groups when comparing total B-cell 
proportions in the splenocytes (Figure 4.22). The analysis of the GCB proportions in 
the splenocytes comfirmed our earlier observations (Figure 4.22). While the LCR hets 
and Bcl6 hets form GCB  (fewer than WT), GC formation in the double hets is 
completely abrogated.  The statistics for the differences between the groups are 
mentioned in the figure. 
 
4.3 Materials and Methods 
 
4.3.1 Germinal Center Formation Assay-Flow Cytometry Analysis 
 For assessment of germinal center formation defects, the mice were intra-
peritonealy injected with 500ul of 1:10 diluted (in D-PBS) sheep red blood cells. On 
day 10 post-immunization the mice were euthanized with CO2 and the spleens were 
collected. One half of the spleen was crushed on a 70-micron filter and the splenocytes 
were suspended in RPMI, 10% FBS and 5mM EDTA. The splenic mononuclear cells 
are separated from the cell suspension using Fico/Lite-LM (Atlanta Biologicals). The 
cells were then stained with antibody mixes specific for germinal center B 
cells(B220+, IgD-, Fas+, CD38- or B220+, IgD-, Fas+, GL7+), naïve B cells (B22, 
centroblasts, centrocytes, follicular zone B cells (B220+, CD23hi, CD21lo), marginal 
zone B cells (B220+, CD23lo, CD21hi), and monocytes (B220-, CD3-, CD11b+, 
GR1+). DAPI was used for live//dead cell staining. The cells were analysed in a BD 
FACS Canto II flow cytometer. 
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4.3.2 Staining splenocytes for T-follicular helper cell analysis via flow cytometry 
 Antigens used for TFH cell staining include, CD3, CD4, CXCR-5 and PD-1 
(fixed cells can be stained with Foxp3 to different regulatory TFH cells after fixing and 
permeabilizing).  However, due to the lack of a functional fluorophore conjugated 
anti-CXCR-5 antibody, we utilized a biotin-streptavidin based system to stain 
splenocytes for analysis.  The splenocytes were processed with RBC lysis solution for 
10 minutes (or with mouse-Ficol), washed with FACS buffer (PBS + 0.5% BSA + 
0.1% Sodium Azide) and subsequently centrifuged at 300 X g for 5 minutes. Primary 
ab (Rat anti-mouse CXCR5 purified 2G8 from BD) was diluted 1:100 in FACS stain 
buffer.  
 
CXCR5 staining was performed before adding any of the other fluorophore-
antibodies. Staining was performed in 96-well v-bottom plates for flow cytometry. 
50ul of the Fc-block diluted 1:500 in FACS buffer was added to the wells with 
splenocytes and incubated for 30 minutes. Cells were then washed once with FACS 
buffer. Removed buffer and added 50ul of 1:100 primary rat-anti-mouse CXCR5 per 
10^6 cells. Incubated for at least 60 minutes at 4-degree C, and then washed twice 
with FACS buffer. Added secondary antibody (conjugated to biotin), diluted 1:1000 in 
FACS buffer with serum (PBS + 0.5% BSA + 0.1% Sodium Azide + 2% NMS + 2% 
FCS). Incubated for 30 minutes at 4-degree C. Cells were washed twice with FACS 
buffer. Stained with SA-Fluorophore (SA-PECy7/SA-APC) at 1:100 dilution in FACS 
buffer with serum. Incubated for another 30 minutes at 4-degree C. 
Added remaining surface stains (CD4, PD-1, B220) and incubated for another 60 
minutes. Washed thrice with FACS buffer and immediately analyze the samples on the 
flow cytometer.  
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4.3.3 Immunohistochemistry 
 Spleen, Bone marrow, Heart, Lung and Brain tissue are fixed in formalin for 
24 hours and then transferred to 70% ethanol. Spleens and were fixed in 4% 
paraformaldehyde and embedded in paraffin. Sections of each sample 6 µm in 
thickness were prepared, cleared in xylene and hydrated through a descending alcohol 
series to distilled water. Slides were boiled for 20 mi in citrate antigen retrieval buffer, 
followed by washes under running water. Endogenous peroxidase activity was blocked 
by treatment of the sections for 20 min with 3% hydrogen peroxide in methanol. 
Tissue sections were then incubated overnight at 4-degree C with biotin-conjugated 
peanut agglutinin (Vector Laboratories). After a further wash in TBS, streptavidin–
horseradish peroxidase was added, followed by incubation for 30 min. Horseradish 
peroxidase activity was detected with a DAB kit (Vector Laboratories). Finally, 
sections were counterstained with hematoxylin if necessary. For double staining, 
sections were incubated overnight at 4-degree C with anti-Bcl-6 (N3; Santa Cruz), 
followed incubation for 1 h with biotin-conjugated secondary antibody 
(sc-2030; Santa Cruz). Streptavidin–alkaline phosphatase was added after a 
further wash in TBS followed by incubation for 30 min. Alkaline phosphatase 
activity was detected with an Alkaline Phosphatase Substrate Kit III (Vector 
Laboratories). Sections were boiled for 10 min followed by incubation with 
biotin-conjugated anti-B220 (RA3-6B2; Caltag Metsystems), then incubation 
with streptavidin–horseradish peroxidase. Horseradish peroxidase activity was 
detected with a DAB kit (Vector Laboratories). 
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4.3.4 Bone marrow transplant 
 6-7-week-old WT-GFP (2 mice), WT C57BL/6-non GFP (2 mice), and LCR 
KO (1 mouse) were sacrificed under CO2. The tibia and fibula bones were 
immediately removed from the sacrificed mice and placed in cold RPMI media. After 
removing muscle and connective tissue from the bones, we isolated the bone marrow 
and counted the cells using a hemocytometer. The cells were resuspended in cold 
sterile D-PBS. The bone marrows were subsequently mixed in ratios required for the 
experiment. The mixed suspensions were centrifuged for 5 minutes at 400 X g at 4 
degree C. The supernatant was removed and the suspension was resuspended in cold 
D-PBS to a final concentration of 10 million per ml. A total of 22, 10-week old, 
female Rag-/- mice were irradiated with 900 cy (450 X 2 over a course of 24 hours) 
prior to transplant.  4 hours after the second dose of radiation, the transplant was 
performed via tail I.V. injection (100ul of suspension per mouse). Mice were observed 
for morbidity post-transplant every week. Mice were immunized with SRBC for 
assessment of GC formation response 4-weeks post-transplant. 
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Chapter 5-Studying the LCR ex-vivo in B-cell Follicular Organoids  
 
5.1 Introduction 
  If there is anything like a good problem in science, then this is it—the 
discovery of a phenotype that is so dramatic, so stark that it obliterates the system you 
wish to detect the defect within. The lack of GC B-cells in the LCR KO mice 
presented us with such a problem. Our efforts to study the mechanism of LCR 
engagement and its specific effects on gene regulation refocused our attention to ex-
vivo cell culture systems. Our two main options were: 1. Utilize human DLBCL cell 
lines, or, 2. Culture LCR KO B-cells from the murine spleens ex-vivo. While both 
approaches have their benefits, each one had its own set of challenges.  
  
We started off with attempts aimed at knocking out the LCR in OCI-Ly7 cells, 
which are derived from GCB like DLBCL cell lines. While the cell line has a mutation 
burden which could complicate the process of elucidating the nuances the LCR 
exhibits in GCBs, it is still useful as the cells have a normal ploidy, wildtype Bcl6, 
Crebbp, Mll4, Ezh2 and Ep300, and wildtype CGH karyotype (Chang, Blondal, 
Benchimol, Minden, & Messner, 1995; Mehra, Messner, Minden, & Chaganti, 2002). 
The doubling time of these cells is approximately 29 hours. However, most attempts to 
utilize CRISPR to delete the LCR in these cell lines failed (data not shown). While a 
deletion product was frequently detected via PCR on the larger population of cells, 
ultimately the isolation of a clone with a deletion failed repeatedly. This was originally 
attributed to the poor ability of single-cell clones of Ly7 to proliferate after performing 
limiting dilutions. We hypothesized that the failure might be due to a deleterious effect 
of the knocked out LCR in these cells.  
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With the attempts around cell line work largely failing, we switched out 
attention to ex-vivo B cell cultures. The primary goal of our experiments at this point 
was to determine if the putative LCR upstream of Bcl6, actually regulated expression 
of Bcl6. The results in the next section depict the manner in which the work evolved 
while highlighting some important realizations about studying chromatin topology and 
transcriptional regulation in such systems.  
 
5.2 Results 
 
5.2.1 Ex-vivo cultures of murine B-cells 
After failing to utilize the human DLBCL cell lines to study the effect of the 
LCR, we started wondering if the B-cells from the LCR KO mice could be cultured 
ex-vivo, long enough to test if Bcl6 expression was indeed influenced. To be able to 
do this we needed a system that would not only allow for the murine B cells to survive 
but also show an induction or maintenance of Bcl6 transcript levels. We started with a 
simple system where we isolated the B-cells from mouse spleens via CD43 depletion 
(which is expressed on all leukocytes except immature and mature B-cells) and grew 
them in RPMI with IL-4, LPS and CD40 antibody. This system has been used for 
activation and proliferation of Immature B-cells ex-vivo (Haxhinasto & Bishop, 2004; 
Rush & Hodgkin, 2001).  
 
Unfortunately, the system did not have any appreciable induction or 
maintenance of Bcl6 expression (Figure 5.1). While we performed qPCR analysis on a 
number of genes either shown to contact the LCR (Klhl6 and Lpp) and the Bcl6 
promoter or known to be important in the GC program (Aicda, Cd86, Cxcr4), 
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however, the analysis did not reveal any appreciable difference in expression between 
LCR KO and WT B-cells. 
Figure	5.1	qPCR	results	from	the	ex-vivo	stimulation	of	CD43	depleted	splenocytes.	Bars	represent	average	fold	change	normalized	to	HPRT	and	compared	to	unstimulated	WT	cells.	Error	bars	are	standard	deviation.	 
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Our efforts then shifted to a co-culture system with the development of a 3D 
B-cell follicle organoid. This utilized 3T3 cells engineered to secrete BAFF and 
express CD40 ligand (CD154) on their surface (Nojima et al., 2011). B-cells cultured 
with these cells (40LB cells), proliferate rapidly in the presence of IL-4, undergo 
isotype switching, and even differentiate into cells that resemble GCBs (upregulation 
of Fas and GL7). An improved version of this culture system, involves the addition of 
a matrix resembling the consistency of the 3D microenvironment of the Germinal 
Center. This is achieved by resuspending the B-cells and the 40LB cells in a gelatin-
based hydrogel and silicate nanoparticles (Purwada & Singh, 2017). These two 
versions of this culture system are depicted in figure 5.2. 
	
Figure	5.2	Schematic	for	B-cell	follicle	culture	system	with	supporting	40LB	cells.	The	left	side	represents	the	version	where	a	3D-matrix	is	provided	in	the	form	of	silica	nanoparticles	and	gelatin,	whereas	the	right	side	lacks	this	matrix.	In	early	iterations	both	systems	were	employed	and	cytokines	were	added	simultaneously.	
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 The promise of utilizing this system was further highlighted in studies 
performed by members of our group when they showed that the B-cells in the 3D 
organoids also undergo somatic hypermutation. Furthermore, at the protein level, both 
BCL6 and EZH2 levels increase around day 4 post plating of the cells. With this 
information in hand, we decided to utilize the organoids to determine if the LCR KO 
B-cells would recapitulate the defect ex-vivo, and more importantly if it would allow 
us to determine the genes that are affected by the loss of the LCR. The results of these 
experiments are below. 
 
5.2.2 Utilizing ex-vivo B-cell follicle cultures to study the LCR 
 Initial efforts with the ex-vivo cultures were to determine if the hypothesized 
effect of the LCR on Bcl6 could be captured. If this were possible, the expectation 
would be that the ex-vivo differentiation of B-cells into GCB-like cells would be 
somewhat compromised in the B-cells from LCR KO mice as compared to WT mice. 
Figure 5.3 shows representative flow cytometry plots for Fas+ GL7+ B-cells (B220+ 
DAPI-) differentiated from splenic B-cells (obtained through CD43 depletion of 
murine spleens) 3-days post plating for both WT and LCR KO mice. In this 
experiment, we performed the plating with and without the nanoparticle-gelatin mix. 
The cells from the nanoparticle-gelatin mix are referred to as ‘organoids’ whereas the 
ones where the B-cells did not have this matrix are referred to as 2D-cultures. 
Surprisingly, the ex-vivo system did not show any major defect between the WT and 
LCR KO mice. The quantification of the GC-like cells from this experiment is shown 
in Figure 5.4, where the error bars represent standard deviation between three 
technical replicates for each genotype and condition. P-values are determined with a 
two-tailed, unpaired t-test.   
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Figure 5.3 Representative flow cytometry plots for GC-like cells from WT (left) and 
LCR KO B-cells (right). The arrows indicate the differentiated cells 3-days post 
plating. (Top) organoid cultures, (bottom) 2D-cultures. 
Figure 5.4 Quantification of the GC-like cells from both organoids and 2D cultures. 
Error bars are standard deviation between technical replicates.   
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 The lack of any defect of GC-like cells in from the LCR KO B-cells led us 
back to the drawing board for the B-cell cultures. Among the numerous purported 
reasons for this anomalous observation, one was the idea that the concentration of 
cytokines being used might be too high. At 50ng/ml of IL-4 and 25 ng/ml of IL-21, we 
wondered if this amount of stimulation did not mimic physiology.  
 
5.2.3 Optimizing the B-cell follicle culture 
 We decided to test if significantly lowered concentrations of IL-4 and IL-21 
would still allow GC-like cell formation, and if so then we should use those 
concentrations to study the LCR. Our curiosity about the dynamics of the signalling 
mechanisms within the organoids led us through a number of experiments where we 
tested the requirement of the system which were otherwise taken for granted. This 
included aspects in addition to the cytokine concentrations including the requirement 
of BAFF and CD154 secreted and expressed by 40-LB cells in the presence of high 
cytokine concentrations; and the requirement of BCL6 itself (i.e. are the organoids 
BCL6 dependant or can they differentiate into GC-like cells from BCL6 KO B-cells as 
well.  
 
We performed an experiment where the organoids were cultured with and 
without 40LB (control cells used for co-culture were 3T3 cells that are the source cells 
for 40-LBs but do not secrete BAFF or express CD154 on their surface), and varied 
concentrations of IL-21 (25 to 0.5 ng/ml). We also tested if 40-LB cells that had been 
culture for 8 weeks showed any reduction in their ability to support the differentiation 
of the B-cells as compared to freshly thawed 40-LB cells that had been through fewer 
passages.  Representative flow plots are shown in figure 5.5 below.  
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Figure 5.5 Representative flow plots of IL-21 titration in the organoid cultures. 80,000 
B-cells were co-cultured with 120,000 40LB or 3T3 cells. (Top) Organoids with 
freshly thawed 40-LB cells, (bottom) organoids with 8-week old 40-LB cells. Right 
most plot is with 3T3 cell which do not secrete BAFF and do not express CD154. 
 
 As is evident from the figure, lower concentrations of IL-21 did not affect the 
differentiation of B-cells, and even 0.5ng/ml of IL-21 is sufficient for differentiation. 
We also confirmed the requirement of BAFF and CD154 (provided by 40LBs) to be 
critical for this differentiation as the organoids with control 3T3 cells had a 
significantly lower proportion of B-cells differentiate as compared to the complete 
organoids. IL-4 concentration for this experiment was maintained at 50ng/ml for all 
conditions. A separate experiment was performed to determine if lower IL-4 
concentrations would be sufficient. That experiment showed similar results, therefore, 
in subsequent experiments the concentrations of both cytokines were lowered.  
 
Additionally, we tested the requirement of BCL6 in the differentiation process 
itself. This was achieved by utilizing spleens from mice that had previously been 
irradiated and transplanted with bone marrow from a BCL6 KO mouse. Surprisingly, 
the organoids plated from these splenocytes showed normal levels of GC-like cell 
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formation. This observation made it necessary to test constitutive knockout B-cells 
directly from a BCL6 KO mouse in culture. Figure 5.6 below shows flow plots for GC 
like cells from (four technical replicates) for WT and BCL6 KO organoids. 
Figure 5.6 Representative flow plots for Fas+GL7+ GC-like cells from (top) WT and 
(bottom) BCL6 KO B-cells (murine).  
 
 The results depicted in figure 5.5 indicate that the organoids are indeed BCL6 
dependant. The GC like cells formed from the irradiated mouse with KO bone marrow 
was most likely due to the incomplete loss of WT bone marrow after irradiation. It is 
possible that even though the dose of radiation was sufficient for lethality, it did not 
result in an absolute abrogation of the host bone marrow. With the transplant of the 
KO bone marrow, the mouse was provided a window of recovery where the KO bone 
marrow (with compromised fitness compared to host WT bone marrow) ended up co-
existing with WT instead of replacing it (akin to a mixed bone marrow chimera). The 
WT cells might have partially populated the spleens and the resulting organoids 
resulted in GC like cell formation due to the presence of those WT cells. Our next step 
was to return to our investigation of the LCR KO mice and test their ability to 
proliferate; to differentiate or to express Bcl6 was in anyway compromised.  
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5.2.4 LCR KO B-cells highlight variability of B-cell follicle cultures 
 With a significantly improved sense of the technical nuances behind the 
organoid cultures, we restarted experiments with WT and LCR KO B-cells. We 
labelled the B-cells with eFluor670, a proliferation dye for the B-cells, to follow the 
rounds of division the cells undergo in culture while differentiating. We also utilized a 
BCL6-PE antibody for flow cytometry to determine if the LCR KO organoids 
displayed any lowering of BCL6 protein levels. Figure 5.6 shows results from one of 
the experiments where the LCR KO cells exhibited an interesting defect.  
Figure 5.7 Representative flow plots (BCL6 vs. proliferation dye efluor 670) of WT, 
LCR KO and BCL6 KO B-cells in organoids 4-days post plating. Smaller plots 
represent the gating (All cells à Singlets à B-cells). Red arrows indicate cell 
divisions (topmost is undivided).  
 The results suggested that the LCR KO cells indeed displayed a defect in GC-
like cell formation when cultured with lower cytokine concentrations. It also showed 
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that the LCR KO organoids had two populations: B-cells with and without BCL6. The 
BCL6 hi cells retained their ability to proliferate normally whereas the sub-population 
of cells with lo BCL6 did not proliferate and mimicked the BCL6 KO phenotype. In 
this experiment the overall percentage of GC like cells in LCR KO was significantly 
less than what was observed for WT cells (figure 5.7).  
Figure 5.8 Plot quantifying the GC-like cells (% of B220+ cells). Error bars are 
standard deviation between four technical replicates. P-values are from unpaired, two-
tailed t-test.  
 
 While these observations were promising, our efforts to replicate this 
phenotype in culture highlighted an important yet disappointing conclusion. 
Variability emerged as the key word for germinal center organoids as numerous 
experiments showed frequently contradicting the observations from figure 5.6 and 5.7.  
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Figure 5.8 below illustrates one such experiment where the difference between LCR 
KO and WT organoids was more or less mitigated. Figure 5.9 shows plots where the 
percentage of GC like cells is plotted for different days along with the level of BCL6 
in total B-cells and the GC-like cells. The figure clearly shows that no significant 
differences were observed in this experiment between WT and KO cells. 
Figure 5.9 Representative flow plots of both B-cell follicle (organoids) and 2D culture 
from LCR KO and WT B-cells (sorted Naïve B-cells) on day-3 and 6 post plating.  
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Figure 5.10 (A) Quantifying the percentage of GC-like cells for experiment depicted 
in figure 5.8. (B) BCL6 levels in all B-cells at different days. (C) BCL6 levels in GC-
like cells at different days. No significant differences observed between the two 
genotypes.  
 
 With the issue of variability highlighted through a number of experiments, we 
decided to try yet another strategy to capture differences between WT and LCR KO 
organoids. We concluded that to better mimic physiology we should offset the 
addition of cytokines in the organoids, only plate sorted Naïve B-cells, and also block 
CD40 signalling through the addition of a blocking antibody. These decisions were 
influenced not only by literature (Zhang et al., 2017) but also through discussions with 
experts in the field who had shared unpublished observations in their laboratories. 
Additionally, we decided to not only test the GC like cell formation trough flow 
cytometry, but also check the transcript levels of Bcl6 and other genes relevant to 
GCB biology via qPCR. We also increased the number of biological replicates by 
incorporating 3 mice in each group. Finally, based on our previous experiences, we 
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concluded that the 2D culture (without the nanoparticles and gelatin) would be 
suitable for the experiment as there no clear reasons to perform the experiment in the 
3D setting. We had previously noted that the addition of nanoparticles created a 
technical challenge during flow assisted sorting of cells, which was needed to get a 
pure population of cells for cDNA prep. Figure 5.10 below highlights the differences 
between the two different systems in terms of cytokine addition.  
5.11 Schematic	for	experiment	with	2D-culture	system	where	cytokine	addition	is	offset.	The	left	side	represents	simultaneous	cytokine	addition,	whereas	the	right	side	represents	the	experimental	arm	where	IL-4	was	added	first	and	IL-21	two	days	post	plating. 
 
 While a pilot experiment with this setup showed promising signs (differences 
observed at the transcript level of Bcl6 and other GC genes), the experiment with three 
biological replicates in each group revealed the true nature of the cells, which was that 
there were no significant differences between the LCR KO GC-like cells and the WT 
GC-like cells (Bcl6 transcript levels shown in figure 5.11). 
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Figure 5.12 qPCR results for Bcl6 levels in WT and LCR KO 2D-cultures (sorted 
GC-like cells) started with sorted Naïve B-cells. Transcript levels are normalized to 
HPRT (housekeeping gene) and to the Bcl6 levels at day 0. The error bars are standard 
error of mean. P-values were calculated via unpaired, two-tailed t-test. No significant 
differences observed.  
 
5.3 Discussion  
 Our integrative study comparing the architecture of the genome in human NB 
and GCB cells reveals a number of mechanisms through which reorganization of 
chromosomal architecture may accommodate and coordinate the rapid changes in 
transcriptional programs. The studies revealed a number of fascinating phenomena, 
which include:  
• Loss of inter-arm chromosomal looping in GCB cells (which is likely the basis 
for the overall nuclear decompaction from NB to GCB. 
• The merging of gene neighbourhoods into gene cities, and the concomitant 
spreading of epigenetic marks across these newly formed gene cities, which is 
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a potential mechanism to efficiently and quickly coordinate gene expression of 
multiple genes.  
• An increase in overall interactions in key loci revealed through Hi-C and 4C 
experiments. This includes both the BCL6 promoter and the upstream LCR 
experiencing increased connectivity with promoters of other genes relevant to 
GCB differentiation and enhancers associated with such genes respectively.  
• 5’ to 3’ gene looping for reloading of RNA polymerase II for highly expressed 
genes. 
 
Through the epigenetic profiling of histone modifications, transcription factor 
ChIP-seqs, and utilization of chromosomal conformation capture techniques, we 
identified a putative LCR upstream of BCL6 which displayed all the features of a cell-
specifying regulatory element. The project I undertook to study the potential role of 
this LCR in a model organism with very little homologous information was, to a 
certain extent, a leap of faith. While the human data held a lot of promise, the 
generation of a new mouse model was a step that had to be taken, and it benefitted 
immensely from the newly available genome editing technique—CRISPR. The 
successful generation of the LCR KO mouse model was a surprise due to the fact that 
the expected deletion was unusually large at ~166Kb. The fact that the entire process 
took less than 6 months is a testament to CRISPR as a technique that is not only 
allowing us to easily attempt genetic alterations, but also making the entire endeavor 
achievable at a much faster pace.  
 
The results of my thesis research prove that the enhancer cluster upstream of 
Bcl6 is required for germinal center formation in mice, and the extensive phenotyping 
illustrates that this cluster has the hallmark characteristics of LCRs. Specifically, the 
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lack of any effect on BCL6 expression in tissues other than GCBs highlights the role 
of the LCR as a regulatory element that controls the fate of one specific cell type. The 
mixed bone marrow chimera experiment was performed to determine if the lack of 
germinal center formation upon SRBC immunization (which should trigger a T-cell 
dependent immune response) was a GCB autonomous defect or not. The alternative 
would have been that the TFH cells were primarily affected by the loss of the LCR, 
which would then have led to a secondary defect in GCB proliferation. The results 
show that the NB and GCB profiling was pointing in the right direction, i.e. the defect 
was intrinsic to GCBs and not manifesting primarily through TFH cells. This is 
especially intriguing, as both GCB and TFH require BCL6 for differentiation. 
Furthermore, ChIP-seq on TFH cells for histone modifications reveal a degree of 
H3K27Ac modifications in the locus that represents the LCR in GCBs, albeit to a 
significantly lower level. It is possible that there is a relatively smaller regulatory role 
of the LCR in TFH cells, but it does not lead to a complete abrogation of the TFH 
compartment. 
 
While the LCR is most likely regulating Bcl6 expression, it has been difficult 
to provide direct evidence of this specific modality due to the complete loss of GCBs 
in the LCR KO mice. The experiment where mice with a single copy of the LCR in 
trans with a single functional BCL6 gene locus exhibit a complete loss of GC 
formation proved to be an elegant solution to this problem. BCL6+/- mice are known to 
have a slight defect in overall GC formation compared to WT mice similar to what is 
observed in LCR+/- mice. While LCRs are known to regulate expression of distal 
genes, there is also evidence that distance from the LCR is negatively correlated with 
the level of expression an LCR can induce (Tanimoto, Liu, Bungert, & Engel, 1999). 
This led us to question if the most proximal gene (in this case BCL6) needed to be in 
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cis with the LCR for it to exert any influence on expression (if it does that at all). 
When the mice exhibited absolute depletion of the GCB cells in the ‘double-hets’, that 
provided, for the first time, a direct link between the LCR and Bcl6. If the LCR had no 
role in regulating Bcl6 expression, the altered positioning of each locus should not 
have led to any exacerbation of the otherwise mild defect in GC formation. While 
establishing the link between the LCR and Bcl6 is an important step in the project, it is 
independently an interesting underlying point that such regulatory elements might not 
function across sister chromosomes. While it is true that an LCR can make far-
reaching contacts with multiple distal genes, it might be that those genes need to be on 
the same chromosome (i.e. be in cis) with the LCR for those interactions to actually 
occur. The current forms of chromosomal conformation capture techniques do not 
make this distinction, and thus far this has not been a question that has been of much 
interest. However, from the perspective of events that occur in the reorganization of 
the genome between distinct cell stages during differentiation, this could prove to be a 
critical concern when studying two or more regulatory loci at the same time.  
 
While we tangentially addressed the question of Bcl6 being regulated by the 
LCR, our inability to study the GCBs lacking the LCR became a major hurdle. To 
address this problem, we decided to focus our attention on DLBCL cell lines and 
primary B-cell cultures from murine splenocytes. Our initial experiments that aimed at 
deleting the LCR in the OCI-Ly7 cell line proved to unsuccessful. At the time the 
failure was attributed to the difficulty in obtaining single cell clones from this cell line, 
which prefers growth in cell clusters. However, subsequent work from other members 
of the Melnick lab proved that critical regulatory motifs exist within the LCR. These 
motifs, when individually targeted (via a CRISPR-interference screen) caused those 
cells to ‘drop-out’ from culture, thereby highlighting the importance of the LCR. My 
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attempts at selecting a clone with the entire LCR deleted were retrospectively proven 
to be a futile experiment.  
 
Switching to B-cell cultures led us into an interesting area of research i.e. the 
effort to emulate in-vivo conditions of the cell type in question. The work that 
surrounded the ambitiously named ‘GC organoids’ proved to be tricky and was 
plagued by a lack of consistent observations in seemingly consistent culture 
conditions. In many ways, the decision to study the effect of the LCR on Bcl6 
transcription ex-vivo, acknowledged the fact that the cultures bypass critical 
physiological cues. For if there existed a hypothetical model that exactly mimicked the 
phenotype, it would prove to be useless as we would not have any cells left to study 
the LCR. The formation of ex-vivo GC-like cells with the help of a few critical 
cytokine signals provided us a chance to attempt a rescue of the cells while still hoping 
to capture a defect at the transcript level. However, the numerous attempts to discern 
such an effect proved to be futile. The ever-present reality is that the culture does not 
capture the temporal nuances, the exact signalling conditions, the true sequence of 
events occurring in a small fraction of B-cells that form germinal centers in-vivo. The 
ex-vivo setup strips down the complexity of the actual physiology behind germinal 
centers to a point where we can only hope to observe the subtleties of locus control 
region mediated regulation. 
 
Many hypothetical scenarios can be put forth to explain the LCR phenotype 
which could also include the reasons why we failed to establish a mechanism of action 
ex-vivo. An important question is the exact moment in B-cell differentiation where 
presence of the LCR is required. While critical, it is a question that is not going to be 
easily addressed for some time, as we do not have working models that can be 
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manipulated in a reliable manner to parse out this particular detail. It is possible that 
the LCR upstream of Bcl6 acts as a critical hub (or be one of many) that assimilates 
the various interleukin and chemokine signals. The convergence of these signals could 
enable the specific reorganization of genomic architecture that subsequently aids the 
initiation of the GC transcriptional reprogramming. The engagement of the LCR may 
be critical at a stage that precedes the events within the germinal center itself i.e. at 
some extremely early stage post antigen stimulation of Naïve B-cells. This might be 
aided by signalling events coordinated between different cell types including TFH cells. 
The fact that the active histone modifications are associated with the LCR in TFH cells 
is highly suggestive of such a mechanism.  
 
If this hypothesis is true (early LCR engagement model), then our failure to 
pick up any reliable defects in the organoids and the 2D cultures can be explained. The 
activation of molecular mechanisms that would allow for effective IL-4 and IL-21 
mediated signalling at the appropriate moment in differentiation could be mediated 
through these potentially early events mediated via the LCR. In the organoids, we 
might be bypassing this requirement by inundating the cells with signals that would 
otherwise by downstream of the LCR. Such an act would effectively rescue the 
phenotype and our observations thus far support such a mechanism. While much of 
this reads as wild speculation, it is not completely out of the realm of possibility. At 
the end of the day, the baffling evolutionary gymnastics that led to the existence of the 
germinal centers surpass what one would imagine being normal, and studying this 
system is a challenge that allows for such conjecture no matter how far fetched it 
might seem.  
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5.4 Materials and Methods 
 
5.4.1 Ex-vivo murine B-cell cultures 
Mouse spleens are collected after sacrificing mice post CO2 mediated 
euthanasia. Spleens are crushed and filtered through a 70-micron filter and 
resuspended in 4 ml of cold buffer (PBS, 5mM EDTA and 2% FBS). The filtered 
splenocytes suspension is gradually layered on top of 3 ml Mouse-Fico-lite in 15 ml 
falcons at room temperature. The cells are centrifuged at 1500 X g for 20 minutes at 
23-degree C. Lymphocytes are collected with a 1 ml pipette by picking up the layer of 
cells between the two phases. The lymphocytes are transferred to another set of 15 ml 
falcons with buffer. This second set of tubes is centrifuged at 300 X g for 5 minutes at 
4-degree C to wash the cells and rid them of residual ficol. Supernatant is aspirated 
and cells are resuspended in 5 ml of cold buffer. Cells are counted using a 
haemocytometer. B-cells are isolated from this suspension using CD43 magnetic 
beads (Miltenyi Biotec Inc. 130049801). Negative selection with the CD43-MACS 
beads isolates ‘untouched’ B-cells that can be cultured ex-vivo. Cells are washed once 
before plating in complete RPMI (10% FBS, HEPES, L-glutamine and 1X 
Penicillin/Streptomycin) with LPS (Sigma L4130) at 25µg/ml, IL-4 (R&D # 404-ML-
010) at 25ng/ml, and anti-CD40 antibody (eBioscience 16-0402-85) at 1µg/ml. Cells 
are plated in 6-well plates at 1 million per ml (total 3 ml per well). Cells are sampled 
at different days for cDNA prep (followed by RNA prep and qPCR) or analysis via 
flow cytometry.  
 
5.4.2 B-cell Follicle Cultures for Differentiation into ‘GCB-Like Cells’ 
 The B-cell follicle culture optimization went through many iterations which 
involved testing differentiation with and without the gelatin-nanoparticle matrix, 
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different cytokine concentrations, co-culturing B-cells with 40LB cells or 3T3 cells, 
and delaying/offsetting cytokine addition. The protocol below describes the steps for 
assembling the organoids in 96 well plates (Sterile, non-pyrogenic, polystyrene, flat 
bottom with low evaporation lids- COSTAR 3595 plates) incorporating all the 
improvements.  
 
40LB cells (BALBc/3T3 cells secreting BAFF and expressing CD154 (or 
CD40L) are adherent cells which are grown in DMEM (with 10%FBS and 1X 
Penicillin-Streptomycin). These cells can be cultured in sterile, non-pyrogenic, 
polystyrene dishes from Corning (Ref# 430167 for 100mm X 20mm, or Ref# 430599 
for 150mm X 25mm dishes). Cells are passaged based on cell-confluence, and the day 
before plating the expected confluency is around 70%. The culture is assembled so as 
to allow B-cell proliferation and differentiation while preventing the 40LB cells from 
dividing themselves. This can be achieved through different means. One way to do 
this is to treat the 40LBs with Mitomycin C (Sigma Aldrich # M0503) at 0.01mg/ml 
for 55 minutes before co-culturing. Mitomycin C from Streptomyces caespitosus is an 
extremely toxic substance and therefore special care is taken while use as well as for 
disposal. Another way to do this is to irradiate the 40LB cells with 3000 rads post-
trypsinization a few hours prior to the co-culture assembly. The irradiation can be 
performed in 50 ml falcon tubes or a 150mm culture dish as long as the cells can be 
transported to the irradiator while maintaining sterile conditions. The irradiator used 
for our experiments is the he Rad Source Technologies RS 2000 Biological Research 
X-ray Irradiator.  The setting used on this machine to irradiate cells involves placing 
the tube/plate on level 5 for 6 minutes and 44 seconds.  
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The B-cells used for culturing are from the spleens of mice. Splenocytes are 
crushed and filtered through a 70-micron filter before processing with the EasySepTM 
Mouse B Cell Isolation kit (StemCell Technologies Inc. #19854). The kit employs an 
immunomagnetic negative selection method that results in the isolation of a >90% 
pure pan-B-cell population. In recent experiments we have started further isolation of 
B220+, IgD+ naïve B-cells via FACS to plate a more homogenous population of B-
cells. If cell proliferation is also being evaluated then we stain the B-cells with the 
proliferation dye eFluor-670 (which is detected in the APC channel on a flow 
cytometer like the BD-Canto II) diluted 1:5000 for 10 minutes at room temperature.  
 
There are two separate forms of the culture based on the addition of a matrix 
component to the cultures. 1. 3D-organoids which involve the addition of porcine 
gelatin and silica-based nanoparticles (Laponite XLG) to the culture. This 
modification is made as an attempt to mimic the extracellular matrix of the B-cell 
follicles and is touted to be better for proliferation and differentiation of the B-cells. 2. 
2D-cultures where the B-cells and 40LB cells are co-cultured in the absence of gelatin 
and nanoparticles.  
 
To prepare the 3D-organoids, we mix the cells in a 1:1 ratio (i.e. 75000 
irradiated 40LB cells are cultured with 75000 sorted naïve B-cells in an organoid in 
each well). The nanoparticles suspension is prepared separately to a 3% (w/v) stock 
solution in sterile water. The nanoparticle suspension is made immediately before 
plating by vortexing the suspension for 3-5 minutes and subsequently filtering the 
suspension through a 0.45-micron filter (can be done with a syringe). The gelatin 
solution is a 5% (w/v) stock that is prepared in complete RPMI medium. The solution 
is mixed and then allowed to dissolve in a 37-degree water bath for 1 hour. The 
	144	
solution is then filtered through a 0.45-micron filter as well. Both the nanoparticles 
and gelatin are prepared in sterile conditions.  
 
The cells—which have been mixed together in the required numbers—are first 
spun down to a pellet by centrifugation at 300 X g for 5 minutes. The supernatant is 
carefully removed and the cells are gently resuspended in gelatin (20ul of gelatin per 
organoid) by pipetting. As the gelatin cools down to room temperature it becomes 
more viscous and therefor difficult to pipette, therefore the cell suspension is placed in 
a 37-degree water bath or incubator until plating begins. The assembly of an organoid 
involves pipetting 20ul of the nanoparticle suspension into a well followed by 
pipetting 20ul of the gelatin-cell suspension into the middle of the nanoparticle 
suspension. The two are gently mixed together by pipetting, and the appropriate media 
with or without cytokines is added before placing the plate in a tissue culture incubator 
set at 37-degree C.  
The media that is added to the culture is complete RPMI (with 10% FBS, 
HEPES, L-glutamine and 1X Penicillin/Streptomycin) with recombinant mouse IL-4 
and IL-21. IL-4 concentration ranges from 50 to 0.5 ng/ml. IL-21 concentration ranges 
from 25 to 2.5 ng/ml (this is specified along with the results for each experiments). 
150 to 200ul of media is added to each well. Cells are collected on day 2, 3 and 4 for 
analysis with flow-cytometry or qPCR.  
 
5.4.3 Fixing, Permeabilizing and Staining Cells for Analysis of Intracellular 
Proteins 
As cells are collected on different days for analysis, we fix the cells with BD 
Cytofix/Cytoperm buffer and stored at 4-degree C until the day the samples are all 
stained together. For simple ex-vivo B-cell cultures we wash the cells once with FACS 
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buffer (PBS with 5mM EDTA and 2% FBS) before fixation. For organoids, we filter 
the cells once through a 45-micron filter to ‘clean up’ the cells (remove some of the 
gelatin and nanoparticles with 40LB cells). The cells are then centrifuged at 400 X g 
for 5 minutes. If fixation is done in a 96-well v bottom plate then 200ul of the BD 
cytofix/cytoperm buffer (Cat. No. 554714) is added to each well and the cells are 
incubated at 4-degree C for 30 minutes. Buffer is washed out via centrifugation an 
aspiration. This is followed by one round of FACS buffer wash with centrifugation. If 
cells are to be processed on another day then the cells are resuspended in buffer and 
can be stored in 4-degree C for up to a week.  
 
 If cells are being permeabilized for intracellular staining then the cells are first 
washed with 1X BD wash buffer (Cat No. 554723). The cells are centrifuged at 900 X 
g for 5 minutes and supernatant is aspirated. 150ul of cold BD Phosflow buffer III 
(Cat. No. 558050) is then added slowly (drop-wise) to the wells and the plate is 
incubated for 30-60 minutes. After the incubation, cells are washed twice with cold 
FACS buffer. The cells are now ready to be stained. For any intracellular stain (e.g. 
BCL6-PE or EZH2-AF488) we also ensure the staining of a few wells with an isotype 
control that is conjugated to the same fluorophore. The typical antigens to be stained 
for are B220, Fas, GL7 and IgD. If experiment had eFluor670 staining then we leave 
the APC channel for the proliferation dye.    
 
5.4.4 RNA and cDNA Preparation for Quantitative PCR Analysis of Genes 
 Cells to be analyzed are resuspended in 1 ml of trizol (100k-1 million cells) 
and incubated at room temperature for 10 minutes. 200ul of chloroform is added to 
each tube (RNase free, 1.5 ml eppendorf tubes) and the samples are vigorously shaken 
before placing them on ice for 15 minutes. Here on all the steps are performed on ice 
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or at 4-degree C in the centrifuge. Samples are centrifuged at 12000 X g for 15 
minutes. The aqueous phase is transferred to another 1.5 ml (RNase free) eppendorf 
tube for each sample (usually 500-600ul of the aqueous phase is collected). Add 500ul 
of isopropanol to the aqueous phase and mix by inverting the tubes 2-3 times. Tubes 
are then transferred to -80-degree C freezer and left overnight to enhance RNA 
precipitation. The next day the samples are centrifuged at 12000 X g fir 10 minutes. 
The RNA pellet is washed with 80% ethanol and air dried for 5 minutes before re-
suspending in sterile, nuclease free water. RNA concentration is measure via Qubit.  
 
 cDNA is prepared for 1ug of the RNA. The RNA concentration should be high 
enough to have 1ug of RNA in a total of 11ul or less. If RNA concentration for even 
one of the samples is less than sufficient for this scenario then the cDNA is prepared 
from a smaller amount (as low as 100ng) for each sample. The verso cDNA synthesis 
kit (AB1453A) is used for this step. cDNA is prepared in a total reaction volume of 
20ul where 11ul is from the sample RNA (we bring up the volume to 11ul with sterile, 
nuclease free water if needed). The remaining 9ul of the reaction included 4ul of 5X 
cDNA synthesis buffer, 2ul of dNTP mix, 1 ul of RNA Primer mix (v/v 3 parts 
random hexamers and 1-part anchored oligo-dT), 1ul of RT enhancer, and 1ul of verso 
enzyme mix (reverse transcriptase). The tubes (PCR tubes) are vortexed and then spun 
down. cDNA is prepared in a thermoycler in 1 cycle (42-degree C for 30 minutes 
à95-degree C for 2 minutes à 4-degree C until samples are removed). The cDNA 
can then be stored at -20-degree C or diluted 40X for qPCR.  
 
 qPCR for genes is performed in a total reaction volume of 10ul in triplicates. 
We use 384 well plates for the experiment. Primers for the genes to be analyzed are 
validated prior to the experiment. 100uM stocks of the primers are diluted to 5uM. 
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The reaction mix per well for qPCR includes 0.5ul of forward and reverse primer mix, 
0.5ul of nuclease free water, 5ul of SYBR Green Total, 4ul of diluted cDNA (or water 
for control). An optical sealing cover is applied on the plate and then the samples are 
centrifuged at 1000g for 1 minute to remove any bubbles. The qPCR run program 
includes 1 cycle at 95-degree C for 20 seconds to activate Taq polymerase, followed 
by 40 cycles of amplification (95-degree C for 20 seconds à 60-degree C for 20 
seconds). This is followed by a dissociation curve cycle. Ct values are analyzed with 
the help of normalizing genes.   
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